DK2357006T3 - Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease - Google Patents

Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease Download PDF

Info

Publication number
DK2357006T3
DK2357006T3 DK11165210.3T DK11165210T DK2357006T3 DK 2357006 T3 DK2357006 T3 DK 2357006T3 DK 11165210 T DK11165210 T DK 11165210T DK 2357006 T3 DK2357006 T3 DK 2357006T3
Authority
DK
Denmark
Prior art keywords
compound
drug
antibody
linker
ligand
Prior art date
Application number
DK11165210.3T
Other languages
Danish (da)
English (en)
Inventor
Peter D Senter
Svetlana Doronina
Brian E Toki
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Application granted granted Critical
Publication of DK2357006T3 publication Critical patent/DK2357006T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK11165210.3T 2002-07-31 2003-07-31 Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease DK2357006T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40040302P 2002-07-31 2002-07-31
EP03772186A EP1545613B9 (en) 2002-07-31 2003-07-31 Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease

Publications (1)

Publication Number Publication Date
DK2357006T3 true DK2357006T3 (en) 2015-12-21

Family

ID=31188683

Family Applications (2)

Application Number Title Priority Date Filing Date
DK03772186.7T DK1545613T3 (da) 2002-07-31 2003-07-31 Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
DK11165210.3T DK2357006T3 (en) 2002-07-31 2003-07-31 Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK03772186.7T DK1545613T3 (da) 2002-07-31 2003-07-31 Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom

Country Status (16)

Country Link
US (5) US7659241B2 (enExample)
EP (3) EP2357006B1 (enExample)
JP (1) JP4741838B2 (enExample)
AT (1) ATE516818T1 (enExample)
AU (2) AU2003263964C1 (enExample)
BE (1) BE2012C047I2 (enExample)
CA (2) CA2494105C (enExample)
CY (2) CY1111894T1 (enExample)
DK (2) DK1545613T3 (enExample)
ES (3) ES2544527T3 (enExample)
FR (1) FR12C0066I2 (enExample)
HU (2) HUE027549T2 (enExample)
LU (1) LU92133I2 (enExample)
PT (2) PT2357006E (enExample)
SI (2) SI1545613T1 (enExample)
WO (1) WO2004010957A2 (enExample)

Families Citing this family (770)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040141983A1 (en) 1999-03-15 2004-07-22 Protein Design Labs, Inc. Compositions against cancer antigen LIV-1 and uses thereof
US7244827B2 (en) 2000-04-12 2007-07-17 Agensys, Inc. Nucleic acid and corresponding protein entitled 24P4C12 useful in treatment and detection of cancer
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US20040018194A1 (en) * 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
US7256257B2 (en) * 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20110313230A1 (en) 2001-05-11 2011-12-22 Terrance Grant Johns Specific binding proteins and uses thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
EP1392359B2 (en) 2001-05-11 2013-03-13 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
ES2606537T3 (es) * 2001-10-23 2017-03-24 Psma Development Company L.L.C. Anticuerpos contra PSMA
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
SI1545613T1 (sl) 2002-07-31 2011-11-30 Seattle Genetics Inc Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
US20040081653A1 (en) * 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
WO2004067564A2 (en) 2003-01-29 2004-08-12 Protein Design Labs, Inc. Compositions against cancer antigen liv-1 and uses thereof
US7662387B2 (en) 2003-02-20 2010-02-16 Seattle Genetics Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US20080025989A1 (en) * 2003-02-20 2008-01-31 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
CA2525929A1 (en) 2003-05-13 2004-11-25 Chiron Corporation Methods of modulating metastasis and skeletal related events resulting from metastases
KR101438983B1 (ko) * 2003-11-06 2014-09-05 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
US20050175619A1 (en) * 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
AU2005216251B2 (en) * 2004-02-23 2011-03-10 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
US7837980B2 (en) * 2004-03-02 2010-11-23 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
EP1789391B1 (en) 2004-07-23 2017-06-28 Endocyte, Inc. Bivalent linkers and conjugates thereof
US8337838B2 (en) 2004-10-15 2012-12-25 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
US7641903B2 (en) * 2004-10-15 2010-01-05 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
US7491390B2 (en) * 2004-10-15 2009-02-17 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
EP1817336B1 (en) 2004-11-12 2019-01-09 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the n terminus
DK1827492T3 (da) 2004-11-30 2010-11-22 Curagen Corp Antistoffer rettet mod GPNMB og anvendelser deraf
WO2006078776A2 (en) 2005-01-19 2006-07-27 The Trustees Of The University Of Pennsylvania Inhibitors and methods of treatment of cardiovascular diseases, and methods for identifying inhibitors
EP2511299A1 (en) 2005-04-19 2012-10-17 Seattle Genetics, Inc. Humanized anti-CD70 binding agents and uses thereof
JP2008546792A (ja) * 2005-06-20 2008-12-25 ピーエスエムエー ディベロップメント カンパニー，エルエルシー Ｐｓｍａ抗体薬物複合体
USRE47223E1 (en) 2005-06-20 2019-02-05 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
EP1917020B1 (en) * 2005-07-07 2016-05-25 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
BRPI0612407A2 (pt) * 2005-07-08 2010-11-03 Elan Pharm Inc preparação de conjugados poliméricos de compostos terapêuticos, agrìcolas e aditivos alimentìcios
HUE035853T2 (en) 2005-07-18 2018-05-28 Seattle Genetics Inc Beta-glucuronide-linker-drug conjugates
NZ566395A (en) 2005-09-26 2012-03-30 Medarex Inc Human monoclonal antibodies to CD70
AR059900A1 (es) 2006-03-17 2008-05-07 Genentech Inc Anticuerpos anti-tat226 e inmunoconjugados
KR20090024166A (ko) * 2006-05-22 2009-03-06 엘란 파마슈티칼스, 인크. 치료학적, 농업적 및 식품 첨가제 화합물의 폴리머 콘주게이트의 제조
PT2032606E (pt) * 2006-05-30 2014-02-05 Genentech Inc Anticorpos e imunoconjugados e respetivas utilizações
WO2008025020A2 (en) * 2006-08-25 2008-02-28 Seattle Genetics, Inc. Cd30 binding agents and uses thereof
DK2502938T3 (en) 2006-10-27 2015-04-20 Genentech Inc Antibodies and immunoconjugates and uses thereof
WO2008070593A2 (en) 2006-12-01 2008-06-12 Seattle Genetics, Inc. Variant target binding agents and uses thereof
WO2008074004A2 (en) * 2006-12-14 2008-06-19 Medarex, Inc. Human antibodies that bind cd70 and uses thereof
US9090693B2 (en) * 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
AU2008216495A1 (en) 2007-02-09 2008-08-21 Genentech, Inc. Anti-Robo4 antibodies and uses therefor
CN101688229B (zh) * 2007-03-15 2013-06-12 路德维格癌症研究所 包含egfr抗体和src抑制剂的组合物及其在制备用于治疗哺乳动物癌症的药物中的用途
BRPI0809435A2 (pt) 2007-03-27 2014-09-09 Sea Lane Biotechnologies, Llc Constructos e bibliotecas que compreendem sequências de cadeia leve substituida de anticorpos
GB0707034D0 (en) 2007-04-12 2007-05-23 St Andrews The Compounds
WO2008141044A2 (en) 2007-05-08 2008-11-20 Genentech, Inc. Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
CA2690943A1 (en) 2007-06-25 2008-12-31 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
JP5469600B2 (ja) 2007-07-16 2014-04-16 ジェネンテック， インコーポレイテッド 抗ＣＤ７９ｂ抗体及びイムノコンジュゲートとその使用方法
EP2176295B1 (en) 2007-07-16 2014-11-19 Genentech, Inc. Humanized anti-cd79b antibodies and immunoconjugates and methods of use
US20090035848A1 (en) * 2007-08-03 2009-02-05 Robert Hickey Moving bed biofilm reactor (mbbr) system for conversion of syngas components to liquid products
CN101896503B (zh) 2007-08-14 2018-05-22 路德维格癌症研究所有限公司 靶向egf受体的单克隆抗体175及其衍生物和用途
SI2187965T1 (sl) 2007-08-17 2020-03-31 Purdue Research Foundation Office Of Technology Commercialization Konjugati vezalca ligand-veznika PSMA in metode za uporabo
CN102099055A (zh) 2007-10-04 2011-06-15 津莫吉尼蒂克斯公司 B7家族成员zB7H6及相关的组合物和方法
KR101641345B1 (ko) 2007-10-12 2016-07-20 시애틀 지네틱스, 인크. 항체-약물 접합체를 이용한 병용 요법
LT2211904T (lt) 2007-10-19 2016-11-25 Seattle Genetics, Inc. Cd19 surišantys agentai ir jų panaudojimas
CA2705486C (en) 2007-11-19 2019-04-02 Celera Corporation Lung cancer markers and uses thereof
EP2078492A1 (de) * 2008-01-11 2009-07-15 Roche Diagnostics GmbH Bandkassette für ein medizinisches Handgerät und Blutzuckermesssystem
US20110033378A1 (en) 2008-01-18 2011-02-10 Medlmmune, Llc. Cysteine Engineered Antibodies For Site-Specific Conjugation
ES2643239T3 (es) 2008-01-31 2017-11-21 Genentech, Inc. Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
EP2265283B1 (en) 2008-03-18 2014-09-03 Seattle Genetics, Inc. Auristatin drug linker conjugates
CA2720699C (en) 2008-04-11 2018-01-02 Seattle Genetics, Inc. Detection and treatment of pancreatic, ovarian and other cancers using antibodies that specifically bind to denatured cd70
KR20230003298A (ko) 2008-04-30 2023-01-05 이뮤노젠 아이엔씨 가교제 및 그 용도
CN102076865B (zh) 2008-05-02 2016-03-16 西雅图基因公司 用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物
US8835506B2 (en) 2008-06-05 2014-09-16 Stc.Unm Methods and related compositions for the treatment of cancer
WO2010027513A2 (en) 2008-09-08 2010-03-11 Psma Development Company, Llc Methods for killing psma-expressing, taxane-resistant cancer cells
GB0819287D0 (en) 2008-10-22 2008-11-26 Univ Bradford Compounds
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
US9211319B2 (en) 2009-01-09 2015-12-15 Seattle Genetics, Inc. Weekly dosing regimens for anti-CD30 VC-PAB-MMAE antibody drug-conjugates
US9238878B2 (en) 2009-02-17 2016-01-19 Redwood Bioscience, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
EP2403524A4 (en) * 2009-03-06 2012-09-26 Agensys Inc CONJUGATES ANTIBODY-DRUG (ADC) BINDING PROTEINS 24P4C12
CN102482345A (zh) 2009-05-13 2012-05-30 航道生物技术有限责任公司 针对流感病毒的中和分子
SG176068A1 (en) 2009-06-03 2011-12-29 Immunogen Inc Conjugation methods
JP5918129B2 (ja) 2009-06-22 2016-05-18 メディミューン，エルエルシー 部位特異的共役のための操作されたＦｃ領域
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CA2775350A1 (en) * 2009-09-24 2011-03-31 Seattle Genetics, Inc. Dr5 ligand drug conjugates
US20110076232A1 (en) * 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
EP2486023A4 (en) 2009-10-06 2014-05-07 Immunogen Inc EFFICIENT CONJUGATES AND HYDROPHILIC BINDER
UA108991C2 (uk) 2009-10-23 2015-07-10 Милленниум Фармасьютикалз, Инк. Молекула антитіла до gcc і пов'язані композиції та способи лікування раку
CA2781887C (en) 2009-11-30 2018-03-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
JP2013513380A (ja) 2009-12-09 2013-04-22 アンスティテュー・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル・（イ・エヌ・エス・ウ・エール・エム） Ｂ７ｈ６と結合するモノクローナル抗体およびその使用
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
JP6046494B2 (ja) 2010-02-08 2016-12-14 アジェンシス，インコーポレイテッド １６１ｐ２ｆ１０ｂタンパク質に結合する抗体薬物コンジュゲート（ａｄｃ）
MX2012009215A (es) * 2010-02-23 2012-11-23 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores.
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
ES2581314T3 (es) * 2010-03-02 2016-09-05 Seattle Genetics, Inc. Métodos de cribado de anticuerpos
EP4450523A3 (en) 2010-04-02 2025-03-12 Amunix Pharmaceuticals, Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
MX368648B (es) 2010-04-15 2019-10-09 Seattle Genetics Inc Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas.
BR112012026801B8 (pt) 2010-04-15 2021-05-25 Medimmune Ltd conjugados de pirrolobenzodiazepina direcionados, composição farmacêutica, uso dos mesmos para tratamento de uma doença proliferativa ou autoimune e ligante de medicamento
MX365521B (es) 2010-04-15 2019-06-06 Oligasis Star Polimeros que contienen zwiteriones de alto peso molecular.
KR20130098165A (ko) 2010-06-03 2013-09-04 제넨테크, 인크. 항체 및 면역접합체의 이뮤노-ｐｅｔ 영상화 및 그의 용도
KR101839163B1 (ko) 2010-06-08 2018-03-15 제넨테크, 인크. 시스테인 조작된 항체 및 접합체
SI2580243T1 (sl) 2010-06-09 2020-02-28 Genmab A/S Protitelesa proti humanemu CD38
EP2579887B1 (de) 2010-06-10 2014-11-12 Seattle Genetics, Inc. Neue auristatin-derivate und ihre verwendung
HRP20171789T1 (hr) 2010-06-15 2017-12-29 Genmab A/S Konjugati humanog protutijela s lijekom protiv tkivnog faktora
US8637641B2 (en) 2010-07-29 2014-01-28 Xencor, Inc. Antibodies with modified isoelectric points
KR20250058780A (ko) 2010-09-29 2025-04-30 어젠시스 인코포레이티드 191p4d12 단백질에 결합하는 항체 약물 컨쥬게이트(ａｄｃ)
ES2553874T3 (es) 2010-09-29 2015-12-14 Seattle Genetics, Inc. N-Carboxialquil-auristatinas y su uso
EP3219731A1 (en) 2010-10-01 2017-09-20 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
WO2012054748A2 (en) 2010-10-22 2012-04-26 Seattle Genetics, Inc. Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway
HRP20170567T1 (hr) 2010-12-06 2017-06-16 Seattle Genetics, Inc. Humanizirana protutijela za liv-1 i njihova uporaba za liječenje raka
TWI589589B (zh) 2010-12-20 2017-07-01 建南德克公司 抗間皮素（ｍｅｓｏｔｈｅｌｉｎ）抗體及免疫接合物
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
AU2012205301B2 (en) 2011-01-14 2017-01-05 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
JP6023097B2 (ja) 2011-03-16 2016-11-09 シアトル ジェネティックス， インコーポレイテッド Ｎカルボキシアルキルオーリスタチンおよびその使用
EP2686020B1 (en) 2011-03-17 2017-02-22 The University of Birmingham Re-directed immunotherapy
WO2012135440A1 (en) 2011-03-30 2012-10-04 Arizona Board Of Regents, For And On Behalf Of, Arizona State University Auristatin tyramine phosphate salts and auristatin aminoquinoline derivatives and prodrugs thereof
JP6177231B2 (ja) 2011-04-20 2017-08-09 ゲンマブ エー／エス Ｈｅｒ２に対する二重特異性抗体
EP2699260B1 (en) 2011-04-20 2024-11-20 Genmab A/S Bispecifc antibodies against her2
JP2014515753A (ja) 2011-04-21 2014-07-03 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 新規な結合剤−薬物複合体（ａｄｃ）およびそれらの使用
EP2707723B1 (en) 2011-05-12 2016-02-10 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
WO2012159027A2 (en) 2011-05-19 2012-11-22 President And Fellows Of Harvard College Osw-1 analogs and conjugates, and uses thereof
WO2012156532A1 (en) 2011-05-19 2012-11-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human-her3 antibodies and uses thereof
UA112434C2 (uk) 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
SG10201605293PA (en) * 2011-05-27 2016-08-30 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
US9796754B2 (en) * 2011-05-27 2017-10-24 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
MX351069B (es) 2011-05-27 2017-09-29 Glaxo Group Ltd Proteinas de union abcma (cd269/tnfrsf17).
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
TWI597065B (zh) 2011-06-10 2017-09-01 梅爾莎納醫療公司 蛋白質－聚合物－藥物共軛體
WO2012177837A2 (en) 2011-06-21 2012-12-27 Immunogen, Inc. Novel maytansinoid derivatives with peptide linker and conjugates thereof
EP2723377B1 (en) 2011-06-22 2018-06-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-axl antibodies and uses thereof
CA2839508A1 (en) 2011-06-22 2012-12-27 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-axl antibodies and uses thereof
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
WO2013015821A1 (en) 2011-07-22 2013-01-31 The Research Foundation Of State University Of New York Antibodies to the b12-transcobalamin receptor
US10300140B2 (en) 2011-07-28 2019-05-28 I2 Pharmaceuticals, Inc. Sur-binding proteins against ERBB3
WO2013022855A1 (en) 2011-08-05 2013-02-14 Xencor, Inc. Antibodies with modified isoelectric points and immunofiltering
EA027971B1 (ru) 2011-09-20 2017-09-29 Медимьюн Лимитед Пирролбензодиазепины
CA2848520C (en) 2011-09-29 2019-11-26 Seattle Genetics, Inc. Intact mass determination of protein conjugated agent compounds
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
WO2013055809A1 (en) 2011-10-10 2013-04-18 Xencor, Inc. A method for purifying antibodies
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
CA2850264C (en) 2011-10-14 2019-11-05 Spirogen Sarl Pyrrolobenzodiazepines
EP2751111B1 (en) 2011-10-14 2017-04-26 MedImmune Limited Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative or autoimmune diseases
MX375987B (es) 2011-10-14 2025-03-07 Seagen Inc Pirrolobenzodiazepinas y conjugados dirigidos
JP6393617B2 (ja) 2011-10-14 2018-09-19 シアトル ジェネティクス，インコーポレーテッド ピロロベンゾジアゼピンおよび標的コンジュゲート
ES2657014T3 (es) 2011-11-17 2018-03-01 Pfizer Inc. Péptidos citotóxicos y conjugados de fármaco anticuerpo de los mismos
US20130224228A1 (en) * 2011-12-05 2013-08-29 Igenica, Inc. Antibody-Drug Conjugates and Related Compounds, Compositions, and Methods
WO2013096828A1 (en) 2011-12-22 2013-06-27 Sea Lane Biotechnologies, Llc Surrogate binding proteins
CA3111357A1 (en) 2011-12-23 2013-06-27 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
CA2858806A1 (en) 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of polypeptides
US9182861B2 (en) 2012-01-12 2015-11-10 Synaptics Incoporated Single layer capacitive imaging sensors
US20150011736A1 (en) 2012-01-20 2015-01-08 Sea Lane Biotechnologies, Llc Binding molecule conjugates
CN104254778A (zh) 2012-02-10 2014-12-31 西雅图遗传学公司 Cd30+癌症的检测和治疗
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
EP2844300B1 (en) 2012-05-01 2018-10-17 Genentech, Inc. Anti-pmel17 antibodies and immunoconjugates
ES2887208T3 (es) 2012-05-15 2021-12-22 Concortis Biosystems Corp Conjugados de fármacos y usos de los mismos
WO2013173337A2 (en) 2012-05-15 2013-11-21 Seattle Genetics, Inc. Self-stabilizing linker conjugates
US9504756B2 (en) 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
US8822423B2 (en) * 2012-05-17 2014-09-02 Janssen Biotech, Inc. Affinity peptides toward infliximab
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
AR091098A1 (es) 2012-05-21 2015-01-14 Genentech Inc ANTICUERPOS E INMUNOCONJUGADOS CONTRA Ly6E Y METODOS DE USO
WO2013174783A1 (en) 2012-05-23 2013-11-28 Pieris Ag Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3
WO2013185114A2 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Chimeric clotting factors
HUE043552T2 (hu) 2012-06-08 2019-09-30 Sutro Biopharma Inc Antitestek, amelyek tartalmaznak helyspecifikus nem természetes aminosav maradékokat, eljárások elõállításukra és eljárások használatukra
EP2858659B1 (en) 2012-06-08 2019-12-25 Bioverativ Therapeutics Inc. Procoagulant compounds
ES2611788T3 (es) 2012-06-26 2017-05-10 Sutro Biopharma, Inc. Proteínas de Fc modificadas que comprenden residuos de aminoácidos no naturales específicos del sitio, conjugados de las mismas, métodos para su preparación y métodos para su uso
EP3632462A1 (en) 2012-07-06 2020-04-08 Genmab B.V. Dimeric protein with triple mutations
EP2869845B1 (en) 2012-07-06 2019-08-28 Genmab B.V. Dimeric protein with triple mutations
US10132799B2 (en) 2012-07-13 2018-11-20 Innate Pharma Screening of conjugated antibodies
CN103566377A (zh) 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
ES2528892T3 (es) 2012-07-30 2015-02-13 Nbe-Therapeutics Llc Identificación mediada por trasposición de proteínas de unión o funcionales específicas
CA2879670A1 (en) 2012-08-02 2014-02-06 Genentech, Inc. Anti-etbr antibodies and immunoconjugates
US9464141B2 (en) 2012-08-02 2016-10-11 Genentech, Inc. Anti-ETBR antibodies and immunoconjugates
KR102274722B1 (ko) 2012-08-23 2021-07-09 어젠시스 인코포레이티드 158p1d7 단백질에 결합하는 항체
EP2890402B1 (en) 2012-08-31 2019-04-17 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
AU2013328673B2 (en) 2012-10-12 2017-07-13 Medimmune Limited Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation
WO2014057120A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-antibody conjugates
AU2013328580B2 (en) 2012-10-12 2016-01-21 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
HRP20180945T1 (hr) 2012-10-12 2018-08-10 Adc Therapeutics Sa Konjugati protutijelo-pirolobenzodiazepin
WO2014057114A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-psma antibody conjugates
EP3470086B1 (en) 2012-10-12 2020-11-25 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
HUE042731T2 (hu) 2012-10-12 2019-07-29 Adc Therapeutics Sa Pirrolobenzodiazepin-antitest konjugátumok
JP6270859B2 (ja) 2012-10-12 2018-01-31 エイディーシー・セラピューティクス・エス・アー・エール・エルＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａｒｌ ピロロベンゾジアゼピン−抗体結合体
AU2013328628B2 (en) 2012-10-12 2016-12-15 Adc Therapeutics Sa Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
IN2015DN04147A (enExample) * 2012-10-16 2015-10-16 Endocyte Inc
CN104755482B (zh) 2012-10-30 2017-04-26 内尔维阿诺医学科学有限公司 官能化的9‑溴‑喜树碱衍生物
JP6694712B2 (ja) 2012-11-01 2020-05-20 マックス−デルブルック−セントラム フアー モレキュラーレ メデジン Ｃｄ２６９（ｂｃｍａ）に対する抗体
HUE036433T2 (hu) 2012-11-05 2018-07-30 Pfizer Spliceostatin analógok
EP2916872B1 (en) 2012-11-09 2019-02-27 Innate Pharma Recognition tags for tgase-mediated conjugation
KR102318999B1 (ko) 2012-11-15 2021-10-29 엔도사이트, 인코포레이티드 Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트
EP2922818B1 (en) 2012-11-24 2018-09-05 Hangzhou Dac Biotech Co., Ltd Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
EP2928503B1 (en) 2012-12-10 2019-02-20 Mersana Therapeutics, Inc. Conjugates of auristatin compounds
JP6334553B2 (ja) 2012-12-10 2018-05-30 メルサナ セラピューティクス，インコーポレイティド タンパク質−高分子−薬剤コンジュゲート
EP2931316B1 (en) 2012-12-12 2019-02-20 Mersana Therapeutics, Inc. Hydroxyl-polymer-drug-protein conjugates
WO2014093671A1 (en) 2012-12-12 2014-06-19 Promega Corporation Compositions and methods for capture of cellular targets of bioactive agents
CA2893977C (en) 2012-12-21 2024-02-13 Seattle Genetics, Inc. Anti-ntb-a antibodies and related compositions and methods
WO2014096551A1 (en) 2012-12-21 2014-06-26 Glykos Finland Oy Linker-payload molecule conjugates
RU2015129800A (ru) 2012-12-21 2017-01-30 Биоэллаенс К. В. Гидрофильные саморазрушающиеся линкеры и их конъюгаты
KR20200134340A (ko) 2013-01-10 2020-12-01 젠맵 비. 브이 인간 IgG1 Fc 영역 변이체 및 그의 용도
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
CA3211863A1 (en) 2013-01-14 2014-07-17 Xencor, Inc. Novel heterodimeric proteins
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
WO2014113510A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
WO2014134483A2 (en) 2013-02-28 2014-09-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
WO2014134486A2 (en) 2013-02-28 2014-09-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
PE20151672A1 (es) 2013-03-14 2015-11-27 Genentech Inc Anticuerpos e inmunoconjugados anti-b7-h4
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
CN110143999B (zh) 2013-03-15 2023-12-05 酵活英属哥伦比亚省公司 具细胞毒性和抗有丝分裂的化合物以及其使用方法
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
TW201945032A (zh) 2013-03-15 2019-12-01 德商艾伯維德國有限及兩合公司 抗-egfr抗體藥物結合物調配物
US10544187B2 (en) 2013-03-15 2020-01-28 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10168323B2 (en) 2013-03-15 2019-01-01 Promega Corporation Compositions and methods for capture of cellular targets of bioactive agents
EP2951203B1 (en) 2013-03-15 2019-05-22 Xencor, Inc. Heterodimeric proteins
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
EP2969435B1 (en) * 2013-03-15 2021-11-03 Promega Corporation Substrates for covalent tethering of proteins to functional groups or solid surfaces
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
AU2014240012A1 (en) 2013-03-15 2015-09-24 Abbvie Inc. Antibody drug conjugate (ADC) purification
WO2014140300A1 (en) 2013-03-15 2014-09-18 Innate Pharma Solid phase tgase-mediated conjugation of antibodies
WO2014177771A1 (en) 2013-05-02 2014-11-06 Glykos Finland Oy Conjugates of a glycoprotein or a glycan with a toxic payload
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
WO2014193722A1 (en) 2013-05-31 2014-12-04 Genentech, Inc. Anti-wall teichoic antibodies and conjugates
GB201309807D0 (en) 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
MX369022B (es) 2013-05-31 2019-10-25 Genentech Inc Anticuerpos anti-ácido teicoico de la pared celular y conjugados.
BR112015030514A2 (pt) 2013-06-04 2017-08-29 Cytomx Therapeutics Inc Composições e métodos para conjugação de anticorpos ativáveis
EP3010547B1 (en) 2013-06-20 2021-04-21 Innate Pharma Enzymatic conjugation of polypeptides
CN105517577A (zh) 2013-06-21 2016-04-20 先天制药公司 多肽的酶促偶联
ES2658039T3 (es) 2013-07-10 2018-03-08 Sutro Biopharma, Inc. Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
TWI646108B (zh) 2013-08-01 2019-01-01 艾澤西公司 結合至ｃｄ３７蛋白質之抗體藥物結合物（ａｄｃ）
GB2516882A (en) 2013-08-02 2015-02-11 Univ Bradford Tumour-targeted theranostic
US9552089B2 (en) 2013-08-07 2017-01-24 Synaptics Incorporated Capacitive sensing using a matrix electrode pattern
MX2016001862A (es) 2013-08-12 2016-08-03 Genentech Inc Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo[e]indol, y metodos de uso y tratamiento.
BR112016004242A8 (pt) 2013-08-28 2018-06-12 Stemcentrx Inc Métodos para conjugação sítio-específica de anticorpos e composições
EA201600252A1 (ru) 2013-09-12 2017-05-31 Галозим, Инк. Модифицированные антитела к рецепторам антиэпидермального фактора роста и способы их использования
HK1218124A1 (zh) 2013-09-17 2017-02-03 豪夫迈．罗氏有限公司 使用抗lgr5抗体的方法
US9298325B2 (en) 2013-09-30 2016-03-29 Synaptics Incorporated Processing system for a capacitive sensing device
US20150091842A1 (en) 2013-09-30 2015-04-02 Synaptics Incorporated Matrix sensor for image touch sensing
US10042489B2 (en) 2013-09-30 2018-08-07 Synaptics Incorporated Matrix sensor for image touch sensing
US9459367B2 (en) 2013-10-02 2016-10-04 Synaptics Incorporated Capacitive sensor driving technique that enables hybrid sensing or equalization
WO2015052535A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
EP3054985B1 (en) 2013-10-11 2018-12-26 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
CN105813655B (zh) 2013-10-11 2022-03-15 阿萨纳生物科技有限责任公司 蛋白-聚合物-药物缀合物
CN105813654B (zh) 2013-10-11 2019-05-31 美国政府(由卫生和人类服务部的部长所代表) Tem8抗体及其用途
CN105979970B (zh) 2013-10-11 2019-09-10 梅尔莎纳医疗公司 蛋白质-聚合物-药物共轭物
EP3055298B1 (en) 2013-10-11 2020-04-29 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
ES2859604T3 (es) 2013-10-11 2021-10-04 Oxford Bio Therapeutics Ltd Anticuerpos conjugados contra LY75 para el tratamiento del cáncer
GB201317981D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
CA3187392A1 (en) * 2013-10-15 2015-04-23 Seagen Inc. Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
RU2016134258A (ru) 2013-10-15 2018-02-28 Сорренто Терапьютикс Инк. Конъюгат лекарственного средства с направляющей молекулой и двумя различными лекарственными средствами
GEP20237497B (en) 2013-10-18 2023-04-10 Deutsches Krebsforsch Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
US9274662B2 (en) 2013-10-18 2016-03-01 Synaptics Incorporated Sensor matrix pad for performing multiple capacitive sensing techniques
JP6707445B2 (ja) 2013-10-21 2020-06-10 ジェネンテック， インコーポレイテッド 抗Ｌｙ６Ｅ抗体及び使用方法
US9495046B2 (en) 2013-10-23 2016-11-15 Synaptics Incorporated Parasitic capacitance filter for single-layer capacitive imaging sensors
US9081457B2 (en) 2013-10-30 2015-07-14 Synaptics Incorporated Single-layer muti-touch capacitive imaging sensor
WO2015069922A2 (en) 2013-11-06 2015-05-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Alk antibodies, conjugates, and chimeric antigen receptors, and their use
BR112016010336A2 (pt) 2013-11-07 2017-10-03 Inst Nat Sante Rech Med Anticorpo anti-humano-her3 alostérico não competitivo com neuregulina, fragmento de anticorpo, sequência de ácido nucleico, vetor, célula hospedeira, composição farmacêutica e método para tratamento de câncer
US20160287731A1 (en) 2013-11-14 2016-10-06 Endocyte, Inc. Compounds for Positron Emission Tomography
EA034123B1 (ru) 2013-11-25 2019-12-30 Сиэтл Дженетикс, Инк. Получение антител для конъюгации из культур клеток cho
US10335494B2 (en) 2013-12-06 2019-07-02 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-CD30 antibodies
SG11201604784XA (en) 2013-12-13 2016-07-28 Genentech Inc Anti-cd33 antibodies and immunoconjugates
BR112016013258A2 (pt) 2013-12-16 2018-01-16 Genentech Inc composto conjugado anticorpo-droga, composição farmacêutica, método para tratar câncer e kit
TWI846009B (zh) 2013-12-19 2024-06-21 美商思進公司 與標的-藥物結合物併用之亞甲基胺基甲酸酯連接物
TWI727919B (zh) 2013-12-19 2021-05-21 美商西雅圖遺傳學公司 與標的-藥物結合物併用之亞甲基胺基甲酸酯連接物
JP6560681B2 (ja) 2013-12-27 2019-08-14 ザイムワークス インコーポレイティド 薬物結合体のためのスルホンアミド含有連結系
KR20160125361A (ko) 2013-12-27 2016-10-31 자임워크스 인코포레이티드 Ｖａｒ２ｃｓａ－약물 접합체
WO2015103549A1 (en) 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
EP3092256B1 (en) 2014-01-10 2022-05-18 Birdie Biopharmaceuticals Inc. Compounds and compositions for immunotherapy
EP3094350B1 (en) 2014-01-15 2020-03-04 The U.S.A. as represented by the Secretary, Department of Health and Human Services Cartilage targeting agents and their use
WO2015112909A1 (en) 2014-01-24 2015-07-30 Genentech, Inc. Methods of using anti-steap1 antibodies and immunoconjugates
AU2015210578B2 (en) 2014-01-29 2020-04-16 Jiangsu Hengrui Medicine Co., Ltd. Ligand-cytotoxic drug conjugate, preparation method therefor, and uses thereof
FR3017298B1 (fr) 2014-02-07 2016-03-04 Centre Nat Rech Scient Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires
WO2015123265A1 (en) 2014-02-11 2015-08-20 Seattle Genetics, Inc. Selective reduction of proteins
KR20160120777A (ko) * 2014-02-17 2016-10-18 시애틀 지네틱스, 인크. 친수성 항체-약물 컨쥬게이트
CN106550593A (zh) 2014-02-21 2017-03-29 艾伯维施特姆森特克斯有限责任公司 用于黑素瘤的抗‑dll3抗体和药物缀合物
US9798429B2 (en) 2014-02-28 2017-10-24 Synaptics Incorporated Guard electrodes in a sensing stack
WO2015127685A1 (en) 2014-02-28 2015-09-03 Hangzhou Dac Biotech Co., Ltd Charged linkers and their uses for conjugation
IL295906A (en) 2014-03-21 2022-10-01 Abbvie Inc Anti-egfr antibodies and antibody drug conjugates
BR112016022385A2 (pt) 2014-03-28 2018-06-19 Xencor, Inc anticorpos específicos que se ligam a cd38 e cd3
US10133421B2 (en) 2014-04-02 2018-11-20 Synaptics Incorporated Display stackups for matrix sensor
US9260478B2 (en) 2014-04-04 2016-02-16 Shanghui Hu Potent and efficient cytotoxic peptides and antibody-drug conjugates thereof and their synthesis
FR3020063A1 (fr) 2014-04-16 2015-10-23 Gamamabs Pharma Anticorps humain anti-her4
US9927832B2 (en) 2014-04-25 2018-03-27 Synaptics Incorporated Input device having a reduced border region
US9690397B2 (en) 2014-05-20 2017-06-27 Synaptics Incorporated System and method for detecting an active pen with a matrix sensor
WO2015189478A1 (en) 2014-06-13 2015-12-17 Glykos Finland Oy Payload-polymer-protein conjugates
JP5924795B2 (ja) 2014-06-13 2016-05-25 テンボロン オイ 複合体
US9950077B2 (en) 2014-06-20 2018-04-24 Bioalliance C.V. Anti-folate receptor alpha (FRA) antibody-drug conjugates and methods of using thereof
WO2015197919A1 (en) 2014-06-25 2015-12-30 Glykos Finland Oy Antibody drug conjugates binding to high-mannose n-glycan
DK3160513T3 (da) 2014-06-30 2020-04-06 Glykos Finland Oy Saccharidderivat af en toksisk payload og antistofkonjugater deraf
PL3169706T3 (pl) 2014-07-11 2020-05-18 Genmab A/S Przeciwciała wiążące axl
WO2016008112A1 (en) 2014-07-16 2016-01-21 Medshine Discovery Inc. Linkers and application towards adc thereof
WO2016014984A1 (en) 2014-07-24 2016-01-28 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
AU2015294389B2 (en) 2014-07-24 2021-04-29 Genentech, Inc. Methods of conjugating an agent to a thiol moiety in a protein that contains at least one trisulfide bond
KR102818922B1 (ko) 2014-08-28 2025-06-11 바이오아트라, 인코퍼레이티드 변형된 t 세포에 대한 조건부 활성 키메라 항원 수용체
CN112587672A (zh) 2014-09-01 2021-04-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
CN107108694B (zh) 2014-09-11 2022-05-03 西雅图基因公司 含叔胺药物物质的靶向递送
PE20170670A1 (es) 2014-09-12 2017-06-06 Genentech Inc Anticuerpos anti-cll-1 e inmunoconjugados
CN106804108B (zh) 2014-09-12 2021-08-10 基因泰克公司 抗-b7-h4抗体及免疫缀合物
SG11201701128YA (en) 2014-09-12 2017-03-30 Genentech Inc Cysteine engineered antibodies and conjugates
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
SG11201701623UA (en) 2014-09-12 2017-03-30 Genentech Inc Anti-her2 antibodies and immunoconjugates
KR102494557B1 (ko) 2014-09-17 2023-02-02 자임워크스 비씨 인코포레이티드 세포독성 및 항유사분열성 화합물, 그리고 이를 이용하는 방법
EP3262071B8 (en) 2014-09-23 2022-05-18 F. Hoffmann-La Roche AG Method of using anti-cd79b immunoconjugates
GB201416960D0 (en) 2014-09-25 2014-11-12 Antikor Biopharma Ltd Biological materials and uses thereof
GB201419108D0 (en) 2014-10-27 2014-12-10 Glythera Ltd Materials and methods relating to linkers for use in antibody drug conjugates
SG11201703446RA (en) 2014-10-31 2017-05-30 Abbvie Biotherapeutics Inc Anti-cs1 antibodies and antibody drug conjugates
JP6785780B2 (ja) 2014-11-05 2020-11-18 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 官能基化モルホリニルアントラサイクリン誘導体
CN107428820B (zh) 2014-11-19 2022-03-22 阿克松神经系统科学公司 在阿尔茨海默氏病中的人源化tau抗体
CN104609464B (zh) * 2014-11-21 2017-01-04 中国科学院电工研究所 一种PbS纳米片的制备方法
US10780096B2 (en) 2014-11-25 2020-09-22 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
SG11201704274QA (en) 2014-11-26 2017-06-29 Xencor Inc Heterodimeric antibodies that bind cd3 and cd38
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
WO2016086189A2 (en) 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies that bind cd3 and tumor antigens
EP3226908A1 (en) 2014-12-03 2017-10-11 F.Hoffmann-La Roche Ag Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof
BR112017011325A2 (pt) 2014-12-03 2020-07-21 Genentech, Inc. ?composto de conjugado anticorpo?antibiótico, composição, método de tratamento de uma infecção, método para matar staph aureus, processo para produzir o conjugado, kit para o tratamento de uma infecção, intermediários antibiótico-ligante e ligante-droga?
BR112017012377A2 (pt) 2014-12-09 2018-04-24 Abbvie Inc conjugados anticorpo-fármaco com inibidores de bcl-xl permeáveis à célula
WO2016091891A1 (en) 2014-12-09 2016-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies against axl
RU2020123953A (ru) 2014-12-09 2020-09-18 Эббви Инк. Ингибирующие bcl-xl соединения, обладающие низкой клеточной проницаемостью, и конъюгаты антитело-лекарственное средство, включающие их
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
US10175827B2 (en) 2014-12-23 2019-01-08 Synaptics Incorporated Detecting an active pen using a capacitive sensing device
US9778713B2 (en) 2015-01-05 2017-10-03 Synaptics Incorporated Modulating a reference voltage to preform capacitive sensing
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
BR112017014599A2 (pt) 2015-01-14 2018-01-16 Bristol-Myers Squibb Company dímeros de benzodiazepina, conjugados dos mesmos, e métodos de preparação e uso
ES2747386T3 (es) 2015-01-14 2020-03-10 Bristol Myers Squibb Co Dímeros de benzodiacepina unidos por heteroarileno, conjugados de los mismos y métodos de preparación y uso
GB201501004D0 (en) 2015-01-21 2015-03-04 Cancer Rec Tech Ltd Inhibitors
CN107849090A (zh) * 2015-01-28 2018-03-27 索伦托医疗有限公司 抗体药物偶联物
WO2016126611A1 (en) 2015-02-02 2016-08-11 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes
EP3265474A1 (en) 2015-03-05 2018-01-10 Sirenas LLC Cyclic peptide analogs and conjugates thereof
WO2016141387A1 (en) 2015-03-05 2016-09-09 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
UA122331C2 (uk) 2015-03-09 2020-10-26 Едженсіс, Інк. Антитіло проти flt3 та кон'югат антитіло-лікарський засіб (adc), який зв'язується з білком flt3
ES2795818T3 (es) 2015-03-18 2020-11-24 Seattle Genetics Inc Anticuerpos CD48 y conjugados de los mismos
US9939972B2 (en) 2015-04-06 2018-04-10 Synaptics Incorporated Matrix sensor with via routing
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
CN106188293A (zh) 2015-04-17 2016-12-07 江苏恒瑞医药股份有限公司 抗c-Met抗体和抗c-Met抗体-细胞毒性药物偶联物及其医药用途
EP3091033A1 (en) 2015-05-06 2016-11-09 Gamamabs Pharma Anti-human-her3 antibodies and uses thereof
US10591465B2 (en) 2015-05-12 2020-03-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for labeling, detection and isolation of Foxp3+ regulatory T cells, isolated population of Foxp3+ regulatory T cells thus obtained and uses thereof
WO2016188911A1 (en) 2015-05-22 2016-12-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies fragments inhibiting both the cath-d catalytic activity and its binding to the lrp1 receptor
WO2016189091A1 (en) 2015-05-26 2016-12-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions (ntsr1 inhibitors) for the treatment of hepatocellular carcinomas
WO2016189118A1 (en) 2015-05-28 2016-12-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of prognosis and treatment of patients suffering from acute myeloid leukemia
EP3845557B1 (en) 2015-06-12 2023-08-02 Lentigen Technology, Inc. Method to treat cancer with engineered t-cells
CN108026123B (zh) 2015-06-15 2021-02-05 杭州多禧生物科技有限公司 用于偶联的亲水链接体
AU2016284340A1 (en) 2015-06-23 2018-02-08 Bristol-Myers Squibb Company Macrocyclic benzodiazepine dimers, conjugates thereof, preparation and uses
FI3316909T3 (fi) 2015-06-30 2023-09-07 Seagen Inc NTB-A-vasta-aineita ja liittyviä koostumuksia ja menetelmiä
US9715304B2 (en) 2015-06-30 2017-07-25 Synaptics Incorporated Regular via pattern for sensor-based input device
US10095948B2 (en) 2015-06-30 2018-10-09 Synaptics Incorporated Modulation scheme for fingerprint sensing
US9720541B2 (en) 2015-06-30 2017-08-01 Synaptics Incorporated Arrangement of sensor pads and display driver pads for input device
CN108368171A (zh) 2015-07-10 2018-08-03 根马布股份公司 用于癌症治疗的axl特异性抗体-药物缀合物
CA2991973C (en) 2015-07-12 2021-12-07 Suzhou M-Conj Biotech Co., Ltd. Bridge linkers for conjugation of a cell-binding molecule
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
ES2860988T3 (es) 2015-07-22 2021-10-05 Inatherys Anticuerpos anti-TFR y su uso en el tratamiento de trastornos proliferativos e inflamatorios
CN205028263U (zh) 2015-09-07 2016-02-10 辛纳普蒂克斯公司 一种电容传感器
US10037112B2 (en) 2015-09-30 2018-07-31 Synaptics Incorporated Sensing an active device'S transmission using timing interleaved with display updates
WO2017058808A1 (en) 2015-10-02 2017-04-06 Sirenas Llc Anti-cancer compounds and conjugates thereof
EP3359570A1 (en) 2015-10-07 2018-08-15 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia
WO2017060397A1 (en) 2015-10-09 2017-04-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of subjects suffering from melanoma metastases
US10421810B2 (en) 2015-10-09 2019-09-24 Lentigen Technology, Inc. Chimeric antigen receptors and methods of use
EP3362088B1 (en) 2015-10-12 2020-11-25 Institut National de la Sante et de la Recherche Medicale (INSERM) An agent capable of depleting cd8 t cells for the treatment of myocardial infarction or acute myocardial infarction
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
WO2017067944A1 (en) 2015-10-19 2017-04-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of subjects suffering from triple negative breast cancer
EP3165237B1 (en) * 2015-11-03 2018-12-19 Industrial Technology Research Institute Antibody-drug conjugate (adc) and method for forming the same
DK3377103T4 (en) 2015-11-19 2025-05-19 Revitope Ltd Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
CA3006610A1 (en) 2015-11-30 2017-06-08 Abbvie Inc. Anti-hulrrc15 antibody drug conjugates and methods for their use
AU2016365114A1 (en) 2015-11-30 2018-05-17 Abbvie Biotherapeutics Inc. Anti-huLRRC15 antibody drug conjugates and methods for their use
CA3006000A1 (en) 2015-12-04 2017-06-08 Seattle Genetics, Inc. Conjugates of quaternized tubulysin compounds
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
CA3007030A1 (en) 2015-12-07 2017-06-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
US10067587B2 (en) 2015-12-29 2018-09-04 Synaptics Incorporated Routing conductors in an integrated display device and sensing device
CN106933400B (zh) 2015-12-31 2021-10-29 辛纳普蒂克斯公司 单层传感器图案和感测方法
MX395252B (es) 2016-01-08 2025-03-25 Altrubio Inc Anticuerpos tetravalentes anti ligando-1 de glicoproteina p-selectina (psgl-1) y usos de estos.
KR20180101479A (ko) 2016-01-13 2018-09-12 젠맵 에이/에스 항체 및 그의 약물 접합체를 위한 제제
UA125718C2 (uk) 2016-01-20 2022-05-25 Зе Скріппс Ресеарч Інстітьют Композиції антитіл до ror1 і пов'язані з ними способи
MX390630B (es) * 2016-01-25 2025-03-21 Regeneron Pharma Derivados de maitansinoide, conjugados de los mismos y metodos de uso.
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
CA3011455A1 (en) 2016-01-27 2017-08-03 Sutro Biopharma, Inc. Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
HUE061880T2 (hu) 2016-02-05 2023-08-28 Rigshospitalet Uparap-ot célzó antitest-gyógyszer konjugátum
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN108778329B (zh) 2016-02-17 2022-09-16 西雅图基因公司 Bcma抗体和其用以治疗癌症和免疫病症的用途
EP3419655A1 (en) 2016-02-27 2019-01-02 The United States of America, as represented by The Secretary, Department of Health and Human Services Peptide vaccines comprising self-assembling polymer nanoparticles
EP3791897A1 (en) 2016-02-29 2021-03-17 Madrigal Pharmaceuticals, Inc. Hsp90 inhibitor drug conjugates
RS62108B1 (sr) * 2016-03-02 2021-08-31 Eisai R&D Man Co Ltd Antitelo-lek konjugati na bazi eribulina i postupci primene
WO2017152083A1 (en) 2016-03-04 2017-09-08 Genentech, Inc. Process for the preparation of an antibody-rifamycin conjugate
MA45324A (fr) 2016-03-15 2019-01-23 Seattle Genetics Inc Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
WO2017162678A1 (en) 2016-03-22 2017-09-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Humanized anti-claudin-1 antibodies and uses thereof
EP3433259B1 (en) 2016-03-24 2021-06-30 The Administrators of The Tulane Educational Fund Conjugates of tacrolimus, their compositions, and their uses
JP7073266B2 (ja) 2016-03-25 2022-05-23 シージェン インコーポレイテッド Ｐｅｇ化薬物リンカー及びその中間体を調製するためのプロセス
EP3438118B1 (en) 2016-03-29 2023-03-29 Toray Industries, Inc. Peptide derivative and use thereof
MA45328A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
JP6735355B2 (ja) 2016-04-15 2020-08-05 バイオアトラ、エルエルシー 抗Ａｘｌ抗体、抗体断片およびそれらの免疫コンジュゲートならびにそれらの使用
US11208632B2 (en) 2016-04-26 2021-12-28 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
WO2017197234A1 (en) 2016-05-13 2017-11-16 Bioatla, Llc Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
US20170348429A1 (en) 2016-05-17 2017-12-07 Abbvie Biotherapeutics Inc. ANTI-cMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
WO2017205741A1 (en) 2016-05-27 2017-11-30 Genentech, Inc. Bioanalytical method for the characterization of site-specific antibody-drug conjugates
EP3464294B1 (en) 2016-05-30 2022-07-13 Toxinvent Oü Antibody-drug-conjugates comprising novel anthracycline-derivatives for cancer treatment
EP3464280B1 (en) 2016-06-06 2021-10-06 F. Hoffmann-La Roche AG Silvestrol antibody-drug conjugates and methods of use
CN109963870B (zh) 2016-06-08 2023-07-28 艾伯维公司 抗b7-h3抗体和抗体药物偶联物
PH12022553314A1 (en) 2016-06-08 2024-05-27 Abbvie Inc Anti-egfr antibody drug conjugates
CA3027046A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
CN109563167A (zh) 2016-06-08 2019-04-02 艾伯维公司 抗b7-h3抗体和抗体药物偶联物
BR112018075649A2 (pt) 2016-06-08 2019-04-09 Abbvie Inc. anticorpos anti-b7-h3 e conjugados de fármaco de anticorpo
WO2017214233A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-egfr antibody drug conjugates
CN109562169A (zh) 2016-06-08 2019-04-02 艾伯维公司 抗cd98抗体及抗体药物偶联物
MX2018015268A (es) 2016-06-08 2019-08-12 Abbvie Inc Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
CA3027181A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-egfr antibody drug conjugates
CA3026151A1 (en) 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
WO2018004338A1 (en) 2016-06-27 2018-01-04 Tagworks Pharmaceuticals B.V. Cleavable tetrazine used in bio-orthogonal drug activation
KR20190020341A (ko) 2016-06-28 2019-02-28 젠코어 인코포레이티드 소마토스타틴 수용체 2에 결합하는 이종이량체 항체
WO2018031690A1 (en) 2016-08-09 2018-02-15 Seattle Genetics, Inc. Drug conjugates with self-stabilizing linkers having improved physiochemical properties
CN106674347B (zh) * 2016-08-16 2019-12-13 滨州医学院 一种新型耳抑素抗体
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US11254705B2 (en) 2016-09-02 2022-02-22 Sirenas Llc Cyclic peptide analogs and conjugates thereof
ES2981703T3 (es) 2016-09-02 2024-10-10 Lentigen Tech Inc Composiciones y métodos para tratar cáncer con DuoCars
US10517958B2 (en) 2016-10-04 2019-12-31 Zymeworks Inc. Compositions and methods for the treatment of platinum-drug resistant cancer
PE20240950A1 (es) 2016-10-14 2024-05-06 Xencor Inc PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa)
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
EA201990890A1 (ru) 2016-10-18 2019-10-31 Целевая доставка ингибиторов реутилизационного пути никотинамидадениндинуклеотида
CN118359705A (zh) 2016-10-19 2024-07-19 英温拉公司 抗体构建体
CA3080270A1 (en) 2016-10-25 2018-05-03 Inserm (Institut National De La Sante Et De La Recherche Medicale) Monoclonal antibodies binding to the cd160 transmembrane isoform
RU2766586C2 (ru) 2016-10-28 2022-03-15 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или предупреждения злокачественной опухоли
BR112019008702A2 (pt) 2016-11-01 2019-07-16 Genmab B.V. polipeptídeo, método de diminuição de uma função fc efetora de um polipeptídeo, composição, método de tratamento, kit de partes, e, uso de um polipeptídeo ou composição.
KR20190074310A (ko) 2016-11-08 2019-06-27 리제너론 파마슈티칼스 인코포레이티드 스테로이드 및 이의 단백질-접합체
CA3042889A1 (en) 2016-11-14 2018-05-17 Millennium Pharmaceuticals, Inc. Non-adult human dosing of anti-cd30 antibody-drug conjugates
KR102345175B1 (ko) 2016-11-14 2021-12-31 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
JP7244987B2 (ja) 2016-12-14 2023-03-23 シージェン インコーポレイテッド 多剤抗体薬物コンジュゲート
EP3554544A4 (en) 2016-12-16 2020-07-29 Bluefin Biomedicine, Inc. ANTI-PROTEIN 1 ANTIBODY CONTAINING AN ANTI-CUB DOMAIN (CDCP1), ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE
US10864279B2 (en) 2016-12-16 2020-12-15 Industrial Technology Research Institute Linker-drug and antibody-drug conjugate (ADC) employing the same
KR102312222B1 (ko) 2016-12-22 2021-10-12 우니베르시따 델리 스투디 만냐 그레챠 카탄차로 Ｃｄ43의 독특한 시알로글리코실화된 암-연관 에피토프를 표적으로 하는 모노클로날 항체
KR102015524B1 (ko) * 2016-12-26 2019-08-29 인터올리고 주식회사 압타머-약물 콘쥬게이트 및 그 용도
CN106854245A (zh) * 2016-12-28 2017-06-16 无锡傲锐东源生物科技有限公司 抗cd30蛋白单克隆抗体及其用途
EP4183798A1 (en) 2017-01-09 2023-05-24 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-mesothelin immunotherapy
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
EP3544636B1 (en) 2017-02-08 2021-03-31 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
EP3579872A1 (en) 2017-02-10 2019-12-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
SI3583125T1 (sl) 2017-02-16 2025-06-30 Sonnet BioTherapeutics, Inc. Fuzijski proteini z albumin-vezavno domeno
US20210330801A1 (en) 2017-03-02 2021-10-28 Cadila Healthcare Limited Novel protein drug conjugate formulation
GB201703876D0 (en) 2017-03-10 2017-04-26 Berlin-Chemie Ag Pharmaceutical combinations
US11730822B2 (en) 2017-03-24 2023-08-22 Seagen Inc. Process for the preparation of glucuronide drug-linkers and intermediates thereof
CA3057838A1 (en) 2017-03-24 2018-09-27 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd33 immunotherapy
MX2019011769A (es) 2017-04-03 2019-11-07 Hoffmann La Roche Anticuerpos que se unen a steap-1.
EP3607319A1 (en) 2017-04-07 2020-02-12 Juno Therapeutics, Inc. Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
CA3059519C (en) 2017-04-18 2021-03-23 Medimmune Limited Pyrrolobenzodiazepine conjugates
EP3612567B1 (en) 2017-04-19 2024-09-11 Bluefin Biomedicine, Inc. Anti-vtcn1 antibodies and antibody drug conjugates
CN110536703B (zh) 2017-04-20 2024-07-12 Adc治疗有限公司 使用抗axl抗体-药物缀合物的组合疗法
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
WO2018201087A1 (en) 2017-04-27 2018-11-01 Seattle Genetics, Inc. Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
WO2018199337A1 (ja) 2017-04-28 2018-11-01 味の素株式会社 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US11666657B2 (en) 2017-05-16 2023-06-06 Universite De Strasbourg Protein-drug conjugates and their use in the treatment of cancers
JP7364471B2 (ja) 2017-05-18 2023-10-18 レゲネロン ファーマシューティカルス，インコーポレーテッド シクロデキストリンタンパク質薬物コンジュゲート
CN111010867B (zh) 2017-05-30 2023-05-12 俄克拉何马大学董事会 抗双皮层蛋白样激酶1抗体及其使用方法
JP7657440B2 (ja) 2017-06-12 2025-04-07 ブルーフィン バイオメディシン， インコーポレイテッド 抗－ｉｌ１ｒａｐ抗体および抗体薬物コンジュゲート
UA127900C2 (uk) 2017-06-14 2024-02-07 Ейдісі Терапьютікс Са Схема дозування для введення adc до cd19
JP7224365B2 (ja) * 2017-06-19 2023-02-17 バイリ－バイオ（チェンドゥ）ファーマスーティカル シーオー．，エルティーディー． 酸性自己安定化ジョイントを有する抗体薬物複合体
CN111315414A (zh) 2017-06-22 2020-06-19 梅尔莎纳医疗公司 产生载药聚合物支架和蛋白-聚合物-药物缀合物的方法
US20210403573A1 (en) 2017-06-22 2021-12-30 INSERM (Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of fibrosis with agents capable of inhibiting the activation of mucosal-associated invariant t (mait) cells
AU2018289581C1 (en) 2017-06-23 2025-01-30 VelosBio Inc. ROR1 antibody immunoconjugates
JP2020526584A (ja) 2017-06-28 2020-08-31 ザ ロックフェラー ユニバーシティー 抗ｍｅｒｔｋアゴニスト抗体−薬物コンジュゲートおよびその使用
AU2018291497A1 (en) 2017-06-30 2020-01-16 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
US20200207859A1 (en) 2017-07-26 2020-07-02 Sutro Biopharma, Inc. Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
JP7237926B2 (ja) 2017-07-31 2023-03-13 レンティジェン・テクノロジー・インコーポレイテッド 抗ｃｄ１９／ｃｄ２０免疫療法によりがんを処置するための組成物および方法
KR102755437B1 (ko) 2017-08-09 2025-01-20 주노 쎄러퓨티크스 인코퍼레이티드 유전자 조작된 세포 조성물 및 관련 조성물의 제조 방법
MX384245B (es) 2017-08-18 2025-03-14 Medimmune Ltd Conjugados de pirrolobenzodiazepina
JP7035170B2 (ja) 2017-09-15 2022-03-14 レンティジェン・テクノロジー・インコーポレイテッド 抗ｃｄ１９免疫療法によりがんを処置するための組成物および方法
RU2020111503A (ru) 2017-09-18 2021-10-20 Сутро Биофарма, Инк. Конъюгаты антитела к рецептору фолиевой кислоты альфа и их применение
JP2020536916A (ja) 2017-10-11 2020-12-17 シアトル ジェネティクス，インコーポレイティド 抗ｃｄ３０抗体薬物複合体療法の副作用を軽減する方法
EP3694883A1 (en) 2017-10-12 2020-08-19 Keio University Anti aqp3 monoclonal antibody specifically binding to extracellular domain of aquaporin 3 (aqp3) and use thereof
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
CN111629735B (zh) 2017-10-16 2024-05-17 莱蒂恩技术公司 用于用抗cd22免疫治疗来治疗癌症的组合物和方法
CN107759699A (zh) * 2017-10-18 2018-03-06 银丰生物工程集团有限公司 靶向cd30抗原的转基因t细胞及其制备方法与应用
JP2021501800A (ja) 2017-11-01 2021-01-21 シアトル ジェネティクス，インコーポレイティド 抗ｃｄ３０抗体薬物複合体療法の副作用を軽減する方法
AU2018360031B2 (en) 2017-11-03 2025-08-21 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-ROR1 immunotherapy
WO2019094395A2 (en) 2017-11-07 2019-05-16 Regeneron Pharmaceuticals, Inc. Hydrophilic linkers for antibody drug conjugates
US11312770B2 (en) 2017-11-08 2022-04-26 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
KR20200090195A (ko) * 2017-11-22 2020-07-28 시애틀 지네틱스, 인크. 리간드-약물 컨쥬게이트의 분석을 위한 산 매개 검정
MX2020005473A (es) 2017-11-27 2020-08-27 Purdue Pharma Lp Anticuerpos humanizados que se dirigen al factor tisular humano.
EP3717519A4 (en) * 2017-11-29 2021-08-25 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS OF DEPLOYMENT FROM CD2 + CELLS
AR113862A1 (es) 2017-12-01 2020-06-17 Seattle Genetics Inc Anticuerpos anti-cd47 y sus usos para tratar cáncer
KR20200090838A (ko) 2017-12-01 2020-07-29 시애틀 지네틱스, 인크. 유방암 치료를 위한 인간화된 항-liv1 항체
US11766455B2 (en) 2017-12-14 2023-09-26 Ezy Biotech Llc Subject-specific tumor inhibiting cells and the use thereof
EP3498293A1 (en) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Treatment of monogenic diseases with an anti-cd45rc antibody
WO2019125732A1 (en) 2017-12-19 2019-06-27 Xencor, Inc. Engineered il-2 fc fusion proteins
AU2018388997B2 (en) 2017-12-20 2025-04-03 Lentigen Technology, Inc. Compositions and methods for treating HIV/AIDS with immunotherapy
AU2019205542B2 (en) 2018-01-08 2025-10-23 Regeneron Pharmaceuticals, Inc. Steroids and antibody-conjugates thereof
CN111989339A (zh) 2018-02-20 2020-11-24 西雅图基因公司 疏水性奥瑞他汀f化合物及其缀合物
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
AU2019232602B2 (en) 2018-03-07 2025-03-27 Forschungsverbund Berlin E.V. Chemoselective thiol-conjugation with alkene or alkyne-phosphonothiolates and -phosphonates
NZ768561A (en) 2018-03-13 2025-09-26 Zymeworks Bc Inc Anti-her2 biparatopic antibody-drug conjugates and methods of use
JP2021518387A (ja) 2018-03-19 2021-08-02 バイオヴェンチャーズ リミテッド ライアビリティ カンパニー ペリオスチン抗体およびその使用方法
MX2020009842A (es) 2018-03-23 2020-10-15 Seattle Genetics Inc Uso de conjugados de anticuerpo-farmaco que comprenden agentes interruptores de tubulina para tratar tumor solido.
WO2019195623A2 (en) 2018-04-04 2019-10-10 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
EP3552631A1 (en) 2018-04-10 2019-10-16 Inatherys Antibody-drug conjugates and their uses for the treatment of cancer
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
JP2021522193A (ja) 2018-04-17 2021-08-30 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 癌を治療する方法
US11505595B2 (en) 2018-04-18 2022-11-22 Xencor, Inc. TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains
CN112867734A (zh) 2018-04-18 2021-05-28 Xencor股份有限公司 包含IL-15/IL-15Ra Fc融合蛋白和PD-1抗原结合结构域的靶向PD-1的异源二聚体融合蛋白及其用途
US11396497B2 (en) 2018-05-04 2022-07-26 New Mexico Tech University Research Park Corporation Proteasome inhibitors
DK3788032T3 (da) 2018-05-04 2024-04-15 Tagworks Pharmaceuticals B V Forbindelser omfattende en linker til øgning af transcyklooctenstabilitet
AU2019262520B2 (en) 2018-05-04 2025-07-10 Tagworks Pharmaceuticals B.V. Tetrazines for high click conjugation yield in vivo and high click release yield
US20210107980A1 (en) 2018-05-07 2021-04-15 Genmab A/S Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
SG11202010993VA (en) 2018-05-07 2020-12-30 Genmab As Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
SG11202010909RA (en) 2018-05-09 2020-12-30 Regeneron Pharma Anti-msr1 antibodies and methods of use thereof
CN112384531B (zh) 2018-06-01 2024-05-14 诺华股份有限公司 针对bcma的结合分子及其用途
AU2019283314B2 (en) 2018-06-05 2024-11-07 GammaDelta Therapeutics Limited BTNL3/8 targeting constructs for delivery of payloads to the gastrointestinal system
TW202519270A (zh) 2018-06-07 2025-05-16 美商思進公司 喜樹鹼結合物
EP3808760A4 (en) 2018-06-14 2022-10-05 Ajinomoto Co., Inc. COMPOUND WITH AFFINITY FOR ANTIBODY, CLEAVAGE SITE AND REACTIVE GROUP OR SALT THEREOF
CN120665147A (zh) 2018-06-14 2025-09-19 味之素株式会社 具有针对抗体的亲和性物质和生物正交性官能团的化合物或其盐
GB201809746D0 (en) 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
MY208638A (en) 2018-07-02 2025-05-21 Amgen Inc Anti-steap1 antigen-binding protein
WO2020023871A1 (en) 2018-07-27 2020-01-30 Promega Corporation Quinone-containing conjugates
SMT202400087T1 (it) 2018-09-11 2024-03-13 Ambrx Inc Coniugati polipeptidici di interleuchina-2 e loro usi
US20220047716A1 (en) 2018-09-17 2022-02-17 Sutro Biopharma, Inc. Combination therapies with anti-folate receptor antibody conjugates
JP7618950B2 (ja) 2018-09-19 2025-01-22 インサーム （インスティテュート ナショナル デ ラ サンテ エ デ ラ ルシェルシェ メディカル） 免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物
JP7546553B2 (ja) 2018-09-20 2024-09-06 レンティジェン・テクノロジー・インコーポレイテッド 抗ｃｄ１２３免疫療法によりがんを処置するための組成物および方法
EP3626265A1 (en) 2018-09-21 2020-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human cd45rc antibodies and uses thereof
WO2020069184A2 (en) 2018-09-26 2020-04-02 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
CA3114137A1 (en) 2018-09-26 2020-04-02 Jiangsu Hengrui Medicine Co., Ltd. Ligand-drug conjugate of exatecan analogue, preparation method therefor and application thereof
KR20210069679A (ko) 2018-10-01 2021-06-11 씨젠 인크. 항-cd30 항체 약물 컨쥬게이트 요법을 사용하여 말초 t 세포 림프종을 치료하는 방법
EP3861016A2 (en) 2018-10-03 2021-08-11 Xencor, Inc. Il-12 heterodimeric fc-fusion proteins
CN113366015A (zh) 2018-10-19 2021-09-07 Ambrx公司 白细胞介素-10多肽缀合物、其二聚体及其用途
TWI824043B (zh) 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物
CA3117050A1 (en) 2018-10-29 2020-05-07 Mersana Therapeutics, Inc. Cysteine engineered antibody-drug conjugates with peptide-containing linkers
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
JPWO2020090979A1 (ja) 2018-10-31 2021-09-24 味の素株式会社 抗体に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
EP3647419A1 (en) 2018-11-02 2020-05-06 NBE Therapeutics AG Sortase f and its use in methods for conjugation
WO2020094609A1 (en) 2018-11-06 2020-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of acute myeloid leukemia by eradicating leukemic stem cells
EP3883610A4 (en) 2018-11-20 2022-11-02 Cornell University MACROCYCLIC COMPLEXES OF RADIONUCLIDES AND THEIR USE IN CANCER RADIATION THERAPY
US11103533B2 (en) 2018-11-30 2021-08-31 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD38 immunotherapy
TWI894130B (zh) 2018-12-03 2025-08-21 美商艾澤西公司 包含抗191p4d12抗體藥物結合物之醫藥組合物及其使用方法
CA3119798A1 (en) 2018-12-06 2020-06-11 Genentech, Inc. Combination therapy of diffuse large b-cell lymphoma comprising an anti-cd79b immunoconjugates, an alkylating agent and an anti-cd20 antibody
EP3894427A1 (en) 2018-12-10 2021-10-20 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
EP3894543A1 (en) 2018-12-14 2021-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Isolated mhc-derived human peptides and uses thereof for stimulating and activating the suppressive function of cd8cd45rc low tregs
WO2020127411A1 (en) 2018-12-19 2020-06-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cancers by immuno-modulation using antibodies against cathespin-d
GB201820864D0 (en) * 2018-12-20 2019-02-06 J A Kemp Antibody-drug conjugates
WO2020127968A1 (en) 2018-12-20 2020-06-25 Marino Stephen F Protein-drug conjugate comprising a monomeric form of proteinase 3
IL319265A (en) 2018-12-21 2025-04-01 Avidity Biosciences Inc Anti-transferrin receptor antibodies and their uses
CA3127113A1 (en) 2019-01-30 2020-08-06 Dongxu Sun Anti-gal3 antibodies and uses thereof
JP7754715B2 (ja) 2019-02-05 2025-10-15 シージェン インコーポレイテッド 抗ｃｄ２２８抗体及び抗体薬物コンジュゲート
KR102788989B1 (ko) 2019-02-15 2025-03-31 우시 엑스디씨 싱가포르 프라이빗 리미티드 동질성이 개선된 항체-약물 콘쥬게이트의 제조방법
US12109273B2 (en) 2019-02-15 2024-10-08 Wuxi Xdc Singapore Private Limited Process for preparing antibody-drug conjugates with improved homogeneity
CN109652384B (zh) * 2019-02-21 2021-10-26 昆明理工大学 一种体外培养戊型肝炎病毒的方法
MX2021010003A (es) 2019-02-26 2021-12-10 Inspirna Inc Anticuerpos anti-mertk de alta afinidad y usos de los mismos.
AU2020232605A1 (en) 2019-03-01 2021-10-21 Xencor, Inc. Heterodimeric antibodies that bind ENPP3 and CD3
CN119932065A (zh) 2019-03-06 2025-05-06 莱蒂恩技术公司 用于用自驱动的嵌合抗原受体来治疗癌症的组合物和方法
AU2020242747B2 (en) 2019-03-15 2025-09-18 Medimmune Limited Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer
CA3133155A1 (en) 2019-03-19 2020-09-24 Fundacio Privada Institut D'investigacio Oncologica De Vall Hebron Combination therapy for the treatment for cancer
JP7682798B2 (ja) 2019-03-20 2025-05-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア クローディン６抗体及び薬物複合体
JP7682797B2 (ja) 2019-03-20 2025-05-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア クローディン６二重特異性抗体
WO2020213084A1 (en) 2019-04-17 2020-10-22 Keio University Anti aqp3 monoclonal antibody specifically binding to extracellular domain of aquaporin 3 (aqp3) and use thereof
EP3962951A1 (en) 2019-05-03 2022-03-09 Sutro Biopharma, Inc. Anti-bcma antibody conjugates
BR112021022225A2 (pt) 2019-05-06 2021-12-28 Centre Nat Rech Scient Composto, pró-droga e composição farmacêutica
CN114206340A (zh) 2019-05-14 2022-03-18 豪夫迈·罗氏有限公司 使用抗cd79b免疫缀合物治疗滤泡性淋巴瘤的方法
US12473265B2 (en) 2019-05-20 2025-11-18 Endocyte, Inc. Methods for preparing PSMA conjugates
JOP20210309A1 (ar) 2019-05-21 2023-01-30 Novartis Ag جزيئات ربط بـ cd19 واستخدامتها
US12037378B2 (en) 2019-05-21 2024-07-16 Novartis Ag Variant CD58 domains and uses thereof
US11052112B2 (en) 2019-05-30 2021-07-06 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-BCMA immunotherapy
WO2020247572A1 (en) 2019-06-05 2020-12-10 Seattle Genetics, Inc. Masked antibody formulations
AR119097A1 (es) 2019-06-05 2021-11-24 Seattle Genetics Inc Métodos de purificación de anticuerpos enmascarados
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
CA3143925A1 (en) 2019-06-17 2020-12-24 Tagworks Pharmaceuticals B.V. Compounds for fast and efficient click release
IL289094A (en) 2019-06-17 2022-02-01 Tagworks Pharmaceuticals B V Tetrazines for increasing the speed and yield of the "click release" reaction
EA202290208A1 (ru) 2019-07-02 2022-03-25 Дзе Юнайтед Стейтс Оф Эмерика, Эз Репрезентед Бай Дзе Секретэри, Дипартмент Оф Хелт Энд Хьюман Сервисиз МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА, КОТОРЫЕ СВЯЗЫВАЮТ EGFRvIII, И ИХ ПРИМЕНЕНИЕ
US20210030885A1 (en) 2019-07-22 2021-02-04 Seagen Inc. Humanized anti-liv1 antibodies for the treatment of cancer
EP4010372A2 (en) 2019-08-06 2022-06-15 GlaxoSmithKline Intellectual Property Development Limited Biopharmacuetical compositions and related methods
TW202120556A (zh) 2019-08-08 2021-06-01 美商再生元醫藥公司 新穎抗原結合分子型式
TWI883032B (zh) 2019-08-12 2025-05-11 中國大陸商北京恩瑞尼生物科技股份有限公司 藉由adcc靶向cd39表現細胞促進及增強t細胞介導免疫反應之方法及組合物
CN114615999B (zh) 2019-09-05 2024-03-08 法马马有限公司 药物抗体偶联物
WO2021052402A1 (zh) 2019-09-18 2021-03-25 四川百利药业有限责任公司 一种喜树碱衍生物及其偶联物
JP2022548306A (ja) 2019-09-19 2022-11-17 シージェン インコーポレイテッド 内部移行した生物学的に活性な化合物の結合体からの選択的な薬物放出
AU2020351751A1 (en) 2019-09-25 2022-04-21 Seagen Inc. Combination anti-CD30 ADC, anti-PD-1 and chemotherapeutic for treatment of hematopoietic cancers
CN114450324B (zh) 2019-09-26 2024-02-27 日油株式会社 具有肽连接子的异双官能单分散聚乙二醇
US20240058466A1 (en) 2019-10-04 2024-02-22 TAE Life Sciences Antibody Compositions Comprising Fc Mutations and Site-Specific Conjugation Properties For Use In Treating Cancer, Immunological Disorders, and Methods Thereof
JP7668791B2 (ja) 2019-10-04 2025-04-25 シージェン インコーポレイテッド 抗ｐｄ－ｌ１抗体および抗体－薬物コンジュゲート
WO2021064184A1 (en) 2019-10-04 2021-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
MX2022004443A (es) 2019-10-18 2022-05-02 Genentech Inc Metodos para usar inmunoconjugados anti-cd79b para tratar linfoma difuso de linfocitos b grandes.
EP3812008A1 (en) 2019-10-23 2021-04-28 Gamamabs Pharma Amh-competitive antagonist antibody
WO2021080608A1 (en) 2019-10-25 2021-04-29 Medimmune, Llc Branched moiety for use in conjugates
WO2021091953A1 (en) 2019-11-05 2021-05-14 Regeneron Pharmaceuticals, Inc. N-terminal scfv multispecific binding molecules
TW202131954A (zh) 2019-11-07 2021-09-01 丹麥商珍美寶股份有限公司 利用鉑類劑與抗組織因子抗體－藥物共軛體之組合來治療癌症之方法
CA3155754A1 (en) 2019-11-07 2021-05-14 Reshma Abdulla RANGWALA Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
EP4247957A1 (en) 2019-11-22 2023-09-27 MedImmune Limited Fusion proteins comprising an e2 ubiquitin or ubiquitin-like conjugating domain and a targeting domain for specific protein degradation
TWI877278B (zh) 2019-12-30 2025-03-21 美商思進公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
CN115052663A (zh) 2020-01-08 2022-09-13 辛瑟斯治疗股份有限公司 Alk5抑制剂缀合物及其用途
CN114845739B (zh) 2020-01-22 2024-07-16 上海森辉医药有限公司 艾日布林衍生物的药物偶联物、其制备方法及其在医药上的应用
US20230095053A1 (en) 2020-03-03 2023-03-30 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
WO2021178896A1 (en) 2020-03-06 2021-09-10 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
KR20220151202A (ko) 2020-03-11 2022-11-14 암브룩스, 인코포레이티드 인터류킨-2 폴리펩타이드 접합체 및 그의 사용 방법
KR20220156867A (ko) 2020-03-19 2022-11-28 어비디티 바이오사이언시스 인크. 안면견갑상완 근이영양증의 치료용 조성물 및 방법
CA3175048A1 (en) 2020-03-25 2021-09-30 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Preparation method for antibody medicament conjugate
BR112022019073A2 (pt) 2020-03-25 2022-11-08 Jiangsu Hengrui Pharmaceuticals Co Ltd Composição farmacêutica que compreende conjugado anticorpo-fármaco e uso da mesma
EP4126066B1 (en) 2020-03-27 2025-11-19 Avidity Biosciences, Inc. Compositions and methods of treating muscle dystrophy
JP2023520773A (ja) 2020-03-27 2023-05-19 ノバルティス アーゲー 増殖性疾患及び自己免疫疾患を治療するための二重特異性組合せ治療
JP2023520930A (ja) 2020-04-10 2023-05-22 シージェン インコーポレイテッド 電荷多様性リンカー
PH12022552706A1 (en) 2020-04-21 2024-03-25 Pharma Mar Sa Drug antibody conjugates
EP4139359A1 (en) 2020-04-24 2023-03-01 Genentech, Inc. Methods of using anti-cd79b immunoconjugates
WO2021221927A1 (en) 2020-04-27 2021-11-04 Parsons Corporation Narrowband iq signal obfuscation
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
CN115968377A (zh) 2020-05-20 2023-04-14 居里研究所 单域抗体及其在癌症治疗中的用途
JP2023528797A (ja) 2020-05-26 2023-07-06 トゥルーバインディング，インコーポレイテッド ガレクチン－３を遮断することにより炎症性疾患を処置する方法
CA3180613A1 (en) 2020-06-05 2021-12-09 Aung MYO Treatment of cd30-positive cancer
EP4163294A4 (en) 2020-06-09 2024-07-24 Ajinomoto Co., Inc. MODIFIED FERRITIN AND METHOD FOR PRODUCING SAME
AU2021296423A1 (en) 2020-06-22 2023-02-02 Lentigen Technology, Inc. Compositions and methods for treating cancer with TSLPR-CD19 or TSLPR-CD22 immunotherapy
CN116322787A (zh) 2020-06-29 2023-06-23 展马博联合股份有限公司 抗组织因子抗体-药物偶联物及其在癌症治疗中的用途
EP4189071A1 (en) 2020-08-03 2023-06-07 Institut National de la Santé et de la Recherche Médicale (INSERM) Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy
AU2021320739A1 (en) 2020-08-04 2023-02-23 Seagen Inc. Anti-CD228 antibodies and antibody-drug conjugates
KR20230166150A (ko) 2020-08-19 2023-12-06 젠코어 인코포레이티드 항-cd28 조성물
CN112062855B (zh) 2020-08-26 2024-08-30 北京天诺健成医药科技有限公司 一种含有衔接器的药物治疗剂的开发和应用
WO2022060905A1 (en) 2020-09-15 2022-03-24 The University Of Montana Compositions and methods targeting filamentous bacteriophage
EP3970752A1 (en) 2020-09-17 2022-03-23 Merck Patent GmbH Molecules with solubility tag and related methods
WO2022067348A1 (en) 2020-09-28 2022-03-31 Seagen Inc. Humanized anti-liv1 antibodies for the treatment of cancer
EP4229090A1 (en) 2020-10-16 2023-08-23 Université d'Aix-Marseille Anti-gpc4 single domain antibodies
WO2022099026A1 (en) 2020-11-05 2022-05-12 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
KR20230104659A (ko) 2020-11-08 2023-07-10 씨젠 인크. 면역 세포 억제제를 이용한 조합-요법 항체 약물 접합체
CN118878694A (zh) 2020-11-23 2024-11-01 康诺亚生物医药科技（成都）有限公司 一种双特异性抗体及其用途
CN114573703A (zh) 2020-12-02 2022-06-03 康诺亚生物医药科技（成都）有限公司 一种t细胞衔接器治疗剂的开发和应用
CN114573702A (zh) 2020-12-02 2022-06-03 康诺亚生物医药科技（成都）有限公司 一种新型肿瘤衔接器治疗药物的开发和应用
CN116782937A (zh) 2020-12-10 2023-09-19 优特力克斯有限公司 抗pd-1抗体及其用途
MX2023007126A (es) 2020-12-23 2023-09-04 Univ Muenchen Ludwig Maximilians Conjugados anticuerpo-droga mejorados dirigidos contra cd30 y usos de los mismos.
CN114685657B (zh) 2020-12-31 2024-08-16 康诺亚生物医药科技（成都）有限公司 一种功能增强型抗体阻断剂的开发及其应用
CN114716548B (zh) 2021-01-05 2024-11-05 (株)爱恩德生物 抗-fgfr3抗体及其用途
CN117916271A (zh) 2021-01-14 2024-04-19 居里研究所 Her2单域抗体变体及其car
EP4279502A1 (en) 2021-01-18 2023-11-22 Ajinomoto Co., Inc. Compound or salt thereof, and antibody obtained therefrom
JP7687350B2 (ja) 2021-01-18 2025-06-03 味の素株式会社 化合物またはその塩、およびそれらにより得られる抗体
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
TW202241508A (zh) 2021-01-29 2022-11-01 美商艾歐凡斯生物治療公司 細胞介素相關之腫瘤浸潤性淋巴球組合物及方法
US12030888B2 (en) 2021-02-24 2024-07-09 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
EP4297794A2 (en) 2021-02-26 2024-01-03 Forschungsverbund Berlin E.V. Cellular uptake of large biomolecules enabled by cell-surface-reactive cell-penetrating peptide additives
WO2022187591A1 (en) 2021-03-05 2022-09-09 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
CA3212665A1 (en) 2021-03-09 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
WO2022192586A1 (en) 2021-03-10 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3
CA3212822A1 (en) 2021-03-11 2022-09-15 Ajinomoto Co., Inc. Compound or salt thereof, and antibody obtained by using the same
JPWO2022196675A1 (enExample) 2021-03-16 2022-09-22
AU2022238571A1 (en) 2021-03-18 2023-09-14 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
JP2024511360A (ja) 2021-03-18 2024-03-13 シージェン インコーポレイテッド 生体活性化合物の内部移行複合体からの選択的薬物放出
KR20240012352A (ko) 2021-03-23 2024-01-29 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) T 세포 림프종의 진단 및 치료 방법
EP4316527A1 (en) 2021-03-31 2024-02-07 MicroBiopharm Japan Co., Ltd. Method for manufacturing antibody-drug conjugate and enzyme used for same
WO2022214681A1 (en) 2021-04-09 2022-10-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of anaplastic large cell lymphoma
EP4319820A1 (en) 2021-04-10 2024-02-14 Profoundbio Us Co. Folr1 binding agents, conjugates thereof and methods of using the same
CA3216410A1 (en) 2021-04-21 2022-10-27 Guy Dipierro Methods of treatment and dosing of natural killer cell compositions
WO2022223783A1 (en) 2021-04-23 2022-10-27 Forschungsverbund Berlin E.V. Thiol-conjugation with unsaturated phosphorus(v) compounds
TW202308699A (zh) 2021-04-23 2023-03-01 美商普方生物製藥美國公司 Ｃｄ７０結合劑、其結合物及其使用方法
JP2024515803A (ja) 2021-04-27 2024-04-10 ベイラー カレッジ オブ メディスン キメラ抗原受容体を発現するウイルス特異的免疫細胞
US11931420B2 (en) 2021-04-30 2024-03-19 Celgene Corporation Combination therapies using an anti-BCMA antibody drug conjugate (ADC) in combination with a gamma secretase inhibitor (GSI)
BR112023023622A2 (pt) 2021-05-12 2024-02-06 Genentech Inc Métodos para tratar linfoma difuso, kits, imunoconjugados, polatuzumabe vedotina e imunoconjugado para uso
WO2022248835A1 (en) 2021-05-26 2022-12-01 Oxford Biotherapeutics Ltd Pharmaceutical combination comprising an anti-cd205 antibody and an immune checkpoint inhibitor
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
US20250026838A1 (en) 2021-07-13 2025-01-23 Truebinding, Inc. Methods of preventing protein aggregation
US20240352080A1 (en) 2021-07-14 2024-10-24 Seagen Inc. Antibody Masking Domains
JP2024530643A (ja) 2021-08-03 2024-08-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド バイオ医薬組成物および安定同位体標識ペプチドマッピング法
US20250101126A1 (en) 2021-08-05 2025-03-27 Go Therapeutics, Inc. Anti-glyco-muc4 antibodies and their uses
US20240336697A1 (en) 2021-08-07 2024-10-10 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
AU2022339667A1 (en) 2021-09-03 2024-04-11 Go Therapeutics, Inc. Anti-glyco-cmet antibodies and their uses
AU2022338463A1 (en) 2021-09-03 2024-03-21 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
WO2023034571A1 (en) 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-lamp1 antibodies and their uses
KR20240099150A (ko) 2021-09-06 2024-06-28 베락사 바이오테크 게엠베하 진핵생물에서의 유전자 코드 확장을 위한 신규 아미노아실-tRNA 합성효소 변이체
FR3126982B1 (fr) 2021-09-14 2023-09-15 Centre Nat Rech Scient Vecteurs ciblant la beta-d-n-acetylglucosaminidase
CN118369344A (zh) 2021-09-16 2024-07-19 阿博莱斯制药公司 抗人cd45rc结合结构域及其用途
EP4401792A4 (en) 2021-09-16 2025-12-03 Avidity Biosciences Inc COMPOSITIONS AND METHODS OF TREATMENT OF FACIO-SCAPULO-HUMERAL MUSCULAR DYSTROPHY
WO2023049825A1 (en) 2021-09-24 2023-03-30 Seagen Inc. Improved antibody masking domains
EP4410830A1 (en) 2021-09-30 2024-08-07 Ajinomoto Co., Inc. Conjugate of antibody and functional substance or salt thereof, and antibody derivative and compound or salts thereof to be used in producing conjugate or salt thereof
CN115975030B (zh) 2021-09-30 2023-09-26 杭州邦顺制药有限公司 抗cd39抗体-药物偶联物及其用途
WO2023054714A1 (ja) 2021-09-30 2023-04-06 味の素株式会社 抗体および機能性物質の位置選択的なコンジュゲートまたはその塩、ならびにその製造に用いられる抗体誘導体および化合物またはそれらの塩
TW202321443A (zh) 2021-10-26 2023-06-01 新加坡商泰莎治療有限公司 用於生產編碼car之反轉錄病毒載體的細胞株
AU2021362997A1 (en) 2021-11-03 2024-05-16 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
PE20242107A1 (es) 2021-11-09 2024-10-28 Tubulis Gmbh Conjugados que comprenden fosforo (v) y una fraccion molecular de droga
CN118524852A (zh) 2021-11-09 2024-08-20 真和制药有限公司 治疗或抑制心血管疾病的方法
MX2024005545A (es) 2021-11-09 2024-07-19 Tubulis Gmbh Conjugados que comprenden fosforo (v) y una fraccion molecular de camptotecina.
JP2024540451A (ja) 2021-11-18 2024-10-31 オックスフォード バイオセラピューティックス リミテッド 組合せ医薬
EP4433096A1 (en) 2021-11-19 2024-09-25 Ardeagen Corporation Gpc3 binding agents, conjugates thereof and methods of using the same
CA3238627A1 (en) 2021-11-25 2023-06-01 Christine Kohler Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
ES3039688T3 (en) 2021-11-25 2025-10-23 Veraxa Biotech Gmbh Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
WO2023104910A1 (en) 2021-12-08 2023-06-15 Tessa Therapeutics Ltd. Treatment of lymphoma
EP4444356A1 (en) 2021-12-08 2024-10-16 European Molecular Biology Laboratory Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates
EP4448095A1 (en) 2021-12-14 2024-10-23 Institut National de la Santé et de la Recherche Médicale (INSERM) Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
US20250099588A1 (en) 2022-01-28 2025-03-27 Iovance Biotherapeutics, Inc. Cytokine associated tumor infiltrating lymphocytes compositions and methods
EP4472740A1 (en) 2022-01-31 2024-12-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Cd38 as a biomarker and biotarget in t-cell lymphomas
EP4372000A3 (en) 2022-02-15 2024-07-17 Tagworks Pharmaceuticals B.V. Masked il12 protein
US11590169B1 (en) 2022-03-02 2023-02-28 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD123 immunotherapy
US20230338424A1 (en) 2022-03-02 2023-10-26 Lentigen Technology, Inc. Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
US20250231193A1 (en) 2022-04-11 2025-07-17 Institut National de la Santé et de la Recherche Médicale Methods for the diagnosis and treatment of t-cell malignancies
JP2025513890A (ja) 2022-04-13 2025-04-30 ティクヴァ アロセル プライベート リミテッド 治療用ｔ細胞製品
WO2023198874A1 (en) 2022-04-15 2023-10-19 Institut National de la Santé et de la Recherche Médicale Methods for the diagnosis and treatment of t cell-lymphomas
AU2023262112A1 (en) 2022-04-29 2024-10-31 Purinomia Biotech, Inc. Methods and compositions for treating eosinophil driven diseases and disorders
JP2025515166A (ja) 2022-05-06 2025-05-13 ジェンマブ エー／エス 抗組織因子抗体－薬物コンジュゲートを用いたがんの治療方法
AU2023301621A1 (en) 2022-06-27 2025-01-02 Foreseen Biotechnology (Shanghai) Co., Ltd. Antibody targeting ITGA2 and antibody-drug conjugate comprising the same
WO2024003310A1 (en) 2022-06-30 2024-01-04 Institut National de la Santé et de la Recherche Médicale Methods for the diagnosis and treatment of acute lymphoblastic leukemia
US20250367307A1 (en) 2022-06-30 2025-12-04 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
MA71328A (fr) 2022-06-30 2025-04-30 Sutro Biopharma, Inc. Anticorps anti-ror1 et conjugués d'anticorps, compositions comprenant des anticorps anti-ror1 ou des conjugués d'anticorps, et méthodes de fabrication et d'utilisation d'anticorps anti-ror1 et de conjugués d'anticorps
AU2023306656A1 (en) 2022-07-15 2025-01-23 Pheon Therapeutics Ltd Antibody drug conjugates that bind cdcp1 and uses thereof
JP2025526336A (ja) 2022-07-22 2025-08-13 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｔ細胞悪性腫瘍におけるバイオマーカー及びバイオターゲットとしてのｇａｒｐ
WO2024025343A1 (ko) 2022-07-26 2024-02-01 (주)에임드바이오 항-ror1 항체 및 이의 용도
JP2025526420A (ja) 2022-07-28 2025-08-13 レンティジェン・テクノロジー・インコーポレイテッド 固形腫瘍を処置するためのキメラ抗原受容体治療
WO2024023283A1 (en) 2022-07-29 2024-02-01 Institut National de la Santé et de la Recherche Médicale Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas
EP4536699A4 (en) * 2022-08-22 2025-10-01 Suzhou Bioreinno Biotechnology Ltd Company METHOD FOR PREPARING AN ANTIBODY HAVING SPECIFIC MODIFICATIONS AT A THIOL GROUP SITE AND USE OF TCEP
JP2025527006A (ja) * 2022-08-22 2025-08-15 スージョウ バイオレイノ バイオテクノロジー リミテッド カンパニー 部位特異的修飾を有する抗体の調製方法
CN119907810A (zh) 2022-08-26 2025-04-29 莱蒂恩技术公司 用于用全人抗cd20/cd19免疫治疗来治疗癌症的组合物和方法
JP2025511436A (ja) 2022-09-02 2025-04-16 メルク・シャープ・アンド・ドーム・エルエルシー エキサテカン由来トポイソメラーゼ－１阻害薬医薬組成物及びその使用
AR130536A1 (es) 2022-09-21 2024-12-18 Seagen Inc Anticuerpos que se unen a cd228
EP4602372A1 (en) 2022-10-12 2025-08-20 Institut National de la Santé et de la Recherche Médicale Cd81 as a biomarker and biotarget in t-cell malignancies
WO2024080872A1 (en) 2022-10-12 2024-04-18 Tagworks Pharmaceuticals B.V. Strained bicyclononenes
EP4605014A1 (en) 2022-10-18 2025-08-27 Tubulis GmbH Novel anti-tpbg antibody and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof
US20240190958A1 (en) 2022-10-18 2024-06-13 Tubulis Gmbh Novel antibody drug conjugates with novel napi2b antibodies, therapeutic methods and uses thereof
IL320482A (en) 2022-10-25 2025-06-01 Peptomyc S L Combination therapy for cancer treatment
TW202432099A (zh) 2022-10-25 2024-08-16 美商默沙東有限責任公司 源自依克沙替康(exatecan)之adc連接子-載藥(payload)、醫藥組合物及其用途
CN120435319A (zh) 2022-11-03 2025-08-05 思进公司 抗-avb6抗体和抗体-药物缀合物及其在癌症治疗中的用途
EP4634227A1 (en) 2022-12-13 2025-10-22 Seagen Inc. Site-specific engineered cysteine antibody drug conjugates
WO2024129614A1 (en) 2022-12-13 2024-06-20 Crinetics Pharmaceuticals, Inc. Somatostatin subtype-2 receptor (sst2r) targeted therapeutics and uses thereof
IL321395A (en) 2022-12-14 2025-08-01 Merck Sharp & Dohme Llc Auristatin cargo-linkers, pharmaceutical compounds, and their uses
GB202219154D0 (en) 2022-12-19 2023-02-01 Metacurum Biotech Ab Antibodies and uses thereof
CN120813386A (zh) 2022-12-22 2025-10-17 Tubulis 股份有限公司 包含磷(v)部分和药物的偶联物
US20240247069A1 (en) 2023-01-13 2024-07-25 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
WO2024153789A1 (en) 2023-01-20 2024-07-25 Basf Se Stabilized biopolymer composition, their manufacture and use
WO2024165484A1 (en) 2023-02-06 2024-08-15 Institut National de la Santé et de la Recherche Médicale Enrichment of genetically modified hematopoietic stem cells through multiplex base editing
AR131815A1 (es) 2023-02-09 2025-05-07 Beigene Ltd Conjugados de enlace autoestabilizantes
WO2024170543A1 (en) 2023-02-14 2024-08-22 Institut National de la Santé et de la Recherche Médicale Anti-cd44 antibodies and uses thereof
CN121100004A (zh) 2023-03-10 2025-12-09 泰克沃尔科斯制药有限公司 具有改进的t-连接子的反式-环辛烯
AU2024238898A1 (en) 2023-03-22 2025-10-16 Salubris Biotherapeutics, Inc. Anti-5t4 antigen binding domains, antibody-drug conjugates and methods of use thereof
AR132196A1 (es) 2023-03-23 2025-06-04 Beigene Switzerland Gmbh Conjugado bioactivo, método de preparación del mismo y uso del mismo
WO2024206738A1 (en) 2023-03-31 2024-10-03 Immunai Inc. Humanized anti-trem2 antibodies
CN120917041A (zh) 2023-04-04 2025-11-07 味之素株式会社 抗体和功能性物质的缀合物、抗体衍生物以及化合物或它们的盐
WO2024210178A1 (ja) 2023-04-05 2024-10-10 味の素株式会社 抗体および機能性物質のコンジュゲートまたはその塩、ならびにチオール基を有する抗体中間体またはその塩
CN116239513B (zh) * 2023-05-05 2023-08-18 天津凯莱英制药有限公司 Mmae关键中间体的制备方法、mmae的制备方法和抗体偶联药物
AU2024269443A1 (en) 2023-05-09 2025-12-11 Shanghai Henlius Biologics Co., Ltd. Anti-epidermal growth factor receptor (egfr) antibody-drug conjugate and use thereof
WO2024236156A1 (en) 2023-05-17 2024-11-21 Institut National de la Santé et de la Recherche Médicale Anti-cathepsin-d antibodies
EP4473974A1 (en) 2023-06-07 2024-12-11 Peptomyc, S.L. Omomyc and kras inhibitors combination therapy for the treatment of cancer
TW202513088A (zh) 2023-06-07 2025-04-01 瓦爾希伯倫私人腫瘤研究基金會 用於治療癌症的與ｍｅｋ抑制劑的組合療法
AU2024285758A1 (en) 2023-06-07 2025-12-18 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Combination therapy with braf inhibitors for the treatment of cancer
WO2024254455A1 (en) 2023-06-08 2024-12-12 Genentech, Inc. Macrophage signatures for diagnostic and therapeutic methods for lymphoma
WO2024258743A1 (en) 2023-06-13 2024-12-19 Adcentrx Therapeutics, Inc. Methods and compositions related to antibodies and antibody drug conjugates (adcs) that bind nectin-4 proteins
WO2024258967A1 (en) 2023-06-13 2024-12-19 Synthis Therapeutics, Inc. Anti-cd5 antibodies and their uses
EP4477236A1 (en) 2023-06-14 2024-12-18 Inatherys Combination therapy for treating a tumor using adc comprising anti-cd71 antibodies and bh3 mimetics
WO2025014896A1 (en) 2023-07-07 2025-01-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Humanized 40h3 antibody
WO2025015318A2 (en) 2023-07-13 2025-01-16 Iovance Biotherapeutics, Inc. Cytokine encoding lentiviral vectors and uses thereof for making tumor infiltrating lymphocytes
WO2025021928A1 (en) 2023-07-25 2025-01-30 Merck Patent Gmbh Iduronidase-cleavable compounds
WO2025021929A1 (en) 2023-07-27 2025-01-30 Veraxa Biotech Gmbh Hydrophilic trans-cyclooctene (hytco) compounds, constructs and conjugates containing the same
WO2025027529A1 (en) 2023-07-31 2025-02-06 Advesya Anti-il-1rap antibody drug conjugates and methods of use thereof
EP4509142A1 (en) 2023-08-16 2025-02-19 Ona Therapeutics S.L. Fgfr4 as target in cancer treatment
WO2025056807A1 (en) 2023-09-15 2025-03-20 Basf Se Stabilized biopolymer composition, their manufacture and use
AU2024201132A1 (en) 2023-09-20 2025-04-10 Uci Therapeutics Inc. Anti-mesothelin antibodies and uses thereof
AR133955A1 (es) 2023-09-26 2025-11-19 Profoundbio Us Co Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos
US20250122306A1 (en) 2023-10-13 2025-04-17 Sutro Biopharma, Inc. Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates
WO2025120015A1 (en) 2023-12-06 2025-06-12 Institut National de la Santé et de la Recherche Médicale Cd5 targeting antibodies with depleting and t or b-cell activation effects
TW202530255A (zh) 2023-12-15 2025-08-01 法商亞維西亞有限公司 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物
US12134635B1 (en) 2023-12-29 2024-11-05 Sonnet BioTherapeutics, Inc. Interleukin 18 (IL-18) variants and fusion proteins comprising same
WO2025149661A1 (en) 2024-01-10 2025-07-17 Genmab A/S Slitrk6 binding agents, conjugates thereof and methods of using the same
WO2025151608A1 (en) * 2024-01-10 2025-07-17 Systimmune, Inc. Connecting units for ligand-drug conjugates and methods of making and using thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025149947A1 (en) 2024-01-12 2025-07-17 Seagen Inc. Antibody-drug conjugates
WO2025163468A1 (en) 2024-01-30 2025-08-07 Seagen Inc. Anti-pd-l1 antibodies and antibody-drug conjugates and their use in the treatment of cancer
WO2025174248A1 (en) 2024-02-16 2025-08-21 Tagworks Pharmaceuticals B.V. Trans-cyclooctenes with "or gate" release
US20250381289A1 (en) 2024-02-29 2025-12-18 Genmab A/S Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
US20250295801A1 (en) 2024-03-21 2025-09-25 Seagen Inc. Cd25 antibodies, antibody drug conjugates, and uses thereof
EP4624494A1 (en) 2024-03-29 2025-10-01 Institut Curie Her2 single domain antibody and uses thereof
WO2025223455A1 (en) 2024-04-24 2025-10-30 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-ptk7/b7h3 antibodies and uses thereof
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
WO2025238052A1 (en) 2024-05-15 2025-11-20 Institut National de la Santé et de la Recherche Médicale Depletion of plasmacytoid dendritic cells for the treatment of respiratory viral infections
WO2025250825A1 (en) 2024-05-30 2025-12-04 Sutro Biopharma, Inc. Anti-trop2 antibodies, compositions comprising anti-trop2 antibodies and methods of making and using anti-trop2 antibodies
WO2025248097A2 (en) 2024-05-31 2025-12-04 Gamamabs Pharma Humanized anti-human her3 antibodies and uses thereof
WO2025248500A1 (en) 2024-05-31 2025-12-04 Janssen Biotech, Inc. Antibody drug conjugates that target enpp3
WO2025257394A1 (en) 2024-06-14 2025-12-18 BioNTech SE Combination therapy for cancer treatment

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3445518A (en) 1966-05-06 1969-05-20 Warner Lambert Pharmaceutical P-acylphenylethylamines
US4414205A (en) 1981-08-28 1983-11-08 University Patents, Inc. Cell growth inhibitory substances
CA1213229A (en) 1982-04-12 1986-10-28 Gary S. David Antibodies having dual specificities, their preparation and uses therefor
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4753894A (en) 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
US5169774A (en) 1984-02-08 1992-12-08 Cetus Oncology Corporation Monoclonal anti-human breast cancer antibodies
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US4694778A (en) 1984-05-04 1987-09-22 Anicon, Inc. Chemical vapor deposition wafer boat
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
US4764368A (en) * 1984-08-29 1988-08-16 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
CA1282069C (en) 1985-09-12 1991-03-26 Damon L. Meyer Antibody complexes of hapten-modified diagnostic or therapeutic agents
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4816444A (en) 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
JPH01202700A (ja) 1988-02-09 1989-08-15 Mitsubishi Electric Corp Ｘ線ミラー及びその製造方法
IL89220A (en) 1988-02-11 1994-02-27 Bristol Myers Squibb Co Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them
US4943628A (en) 1988-06-13 1990-07-24 Ortho Pharmaceutical Corporation HIV peptide-inducted T cell stimulation
DE68925933T2 (de) 1988-08-12 1996-08-14 Fisons Corp Arylalkylamine und -amide mit krampflösender und nervenschützender Wirkung
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US4978744A (en) 1989-01-27 1990-12-18 Arizona Board Of Regents Synthesis of dolastatin 10
US4879278A (en) 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
US5286637A (en) 1989-08-07 1994-02-15 Debiopharm, S.A. Biologically active drug polymer derivatives and method for preparing same
US5165923A (en) 1989-11-20 1992-11-24 Imperial Cancer Research Technology Methods and compositions for the treatment of hodgkin's disease
US5767236A (en) 1990-05-09 1998-06-16 Biomeasure, Inc. Linear therapeutic peptides
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
DE69230824T2 (de) 1991-08-09 2000-07-27 Teikoku Hormone Mfg. Co., Ltd. Neue tetrapeptidderivate
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
WO1994004690A1 (en) 1992-08-17 1994-03-03 Genentech, Inc. Bispecific immunoadhesins
US6569834B1 (en) 1992-12-03 2003-05-27 George R. Pettit Elucidation and synthesis of antineoplastic tetrapeptide w-aminoalkyl-amides
US6034065A (en) 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5410024A (en) 1993-01-21 1995-04-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
JPH06234790A (ja) 1993-02-09 1994-08-23 Teikoku Hormone Mfg Co Ltd 新規テトラペプチドアミド誘導体
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
FR2710536B1 (fr) 1993-09-29 1995-12-22 Transgene Sa Usage anti-cancéreux d'un vecteur viral comportant un gène modulateur de la réponse immunitaire et/ou inflammatoire.
CA2173150C (en) 1993-10-01 2004-11-30 Kyoichi Sakakibara Novel peptide derivatives
US5521284A (en) 1994-08-01 1996-05-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides and esters
US5504191A (en) 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5530097A (en) 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5554725A (en) 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
DE69605181T3 (de) 1995-01-18 2006-08-24 Roche Diagnostics Gmbh Antikörper gegen cd30, die proteolytische spaltung und abgabe des membrangebundenen cd30 antigens verhindern
WO1996033212A1 (fr) 1995-04-21 1996-10-24 Teikoku Hormone Mfg. Co., Ltd. Nouveaux derives peptidiques
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
JPH0977791A (ja) 1995-09-08 1997-03-25 Nippon Kayaku Co Ltd ペプチド誘導体及びその用途
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
US5741892A (en) 1996-07-30 1998-04-21 Basf Aktiengesellschaft Pentapeptides as antitumor agents
EP0961619A4 (en) 1996-09-27 2001-09-26 Bristol Myers Squibb Co HYDROLYSABLE DRUGS FOR THE RELEASE OF ANTI-CANCER DRUGS IN METASTATIC CELLS
WO1998036765A1 (en) 1997-02-25 1998-08-27 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18
US5965537A (en) 1997-03-10 1999-10-12 Basf Aktiengesellschaft Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus
US6143721A (en) 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
EP1045858B1 (en) 1998-01-09 2004-12-08 ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA acting for and on behalf of ARIZONA STATE UNIVERSITY Anti-cryptococcal peptides
US6162930A (en) 1998-03-06 2000-12-19 Baylor University Anti-mitotic agents which inhibit tubulin polymerization
US5985837A (en) * 1998-07-08 1999-11-16 Basf Aktiengesellschaft Dolastatin 15 derivatives
US7425541B2 (en) * 1998-12-11 2008-09-16 Medarex, Inc. Enzyme-cleavable prodrug compounds
ES2313883T3 (es) * 1999-02-12 2009-03-16 The Scripps Research Institute Procedimientos para el tratamiento de tumores y metastasis utilizando una combinacion de terapias antiangiogenicas e inmunoterapias.
US20040141983A1 (en) 1999-03-15 2004-07-22 Protein Design Labs, Inc. Compositions against cancer antigen LIV-1 and uses thereof
CN1308347C (zh) 1999-04-28 2007-04-04 德克萨斯大学董事会 用于通过选择性抑制vegf来治疗癌症的组合物和方法
CA2379274A1 (en) * 1999-07-12 2001-01-18 Genentech, Inc. Blocking immune response to a foreign antigen using an antagonist which binds to cd20
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
EP1272647B1 (en) * 2000-04-11 2014-11-12 Genentech, Inc. Multivalent antibodies and uses therefor
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
US20030083263A1 (en) 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
US6884869B2 (en) * 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20050107595A1 (en) 2001-06-20 2005-05-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7803915B2 (en) 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
US6737409B2 (en) 2001-07-19 2004-05-18 Hoffmann-La Roche Inc. Dolastatin 10 derivatives
US20040235068A1 (en) 2001-09-05 2004-11-25 Levinson Arthur D. Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
US7098305B2 (en) 2001-09-06 2006-08-29 Ardana Bioscience Limited Sustained release of microcrystalline peptide suspensions
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
US20050238650A1 (en) 2002-04-17 2005-10-27 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
ES2606537T3 (es) 2001-10-23 2017-03-24 Psma Development Company L.L.C. Anticuerpos contra PSMA
AU2002363939A1 (en) * 2001-11-20 2003-06-10 Seattle Genetics, Inc. Treatment of immunological disorders using anti-cd30 antibodies
EP1487493B1 (en) 2002-03-01 2010-01-20 The Administrators of The Tulane Educational Fund Conjugates of cytotoxic agents and biologically active peptides
US7288248B2 (en) * 2002-03-08 2007-10-30 Pdl Biopharma, Inc. Antibodies against cancer antigen TMEFF2 and uses thereof
US20050014687A1 (en) 2002-03-19 2005-01-20 Anderson David W. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
SI1545613T1 (sl) 2002-07-31 2011-11-30 Seattle Genetics Inc Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
US20050180972A1 (en) 2002-07-31 2005-08-18 Wahl Alan F. Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders
ATE499116T1 (de) 2002-08-16 2011-03-15 Immunogen Inc Vernetzer mit hoher reaktivität und löslichkeit und ihre verwendung bei der herstellung von konjugaten für die gezielte abgabe von kleinmolekularen arzneimitteln
EP1581171B1 (en) 2002-12-20 2012-06-27 Abbott Biotherapeutics Corp. Antibodies against gpr64 and uses thereof
US7662387B2 (en) 2003-02-20 2010-02-16 Seattle Genetics Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
EP3000886A1 (en) 2003-03-19 2016-03-30 Amgen Fremont Inc. Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
KR101438983B1 (ko) 2003-11-06 2014-09-05 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
AU2005216251B2 (en) 2004-02-23 2011-03-10 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
US7837980B2 (en) 2004-03-02 2010-11-23 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
US7399469B2 (en) 2004-03-26 2008-07-15 Pdl Biopharma, Inc. Anti-LFL2 antibodies for the diagnosis, prognosis and treatment of cancer
US7442332B2 (en) * 2004-05-04 2008-10-28 Clopay Plastic Products Company, Inc. Method and apparatus for uniformly stretching thermoplastic film and products produced thereby
US7312343B2 (en) 2004-06-02 2007-12-25 Hoffmann-La Roche Inc. Synthesis of α-amino-β-alkoxy-carboxylic acid esters
CN104447992A (zh) 2004-09-23 2015-03-25 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
BRPI0516577A (pt) 2004-10-05 2008-09-16 Genentech Inc agentes terapêuticos com toxicidade diminuìda
DK1827492T3 (da) 2004-11-30 2010-11-22 Curagen Corp Antistoffer rettet mod GPNMB og anvendelser deraf
KR20070086128A (ko) 2004-12-13 2007-08-27 에프. 호프만-라 로슈 아게 3-피롤리딘-2-일-프로피온산 유도체의 신규 제조 방법
WO2006083936A2 (en) 2005-01-31 2006-08-10 Genentech, Inc. Anti-ephb2 antibodies and methods using same
WO2006104978A2 (en) 2005-03-25 2006-10-05 Curagen Corporation Antibodies against the tenascin major antigens
JP2008546792A (ja) 2005-06-20 2008-12-25 ピーエスエムエー ディベロップメント カンパニー，エルエルシー Ｐｓｍａ抗体薬物複合体
WO2007030642A2 (en) 2005-09-07 2007-03-15 Medimmune, Inc. Toxin conjugated eph receptor antibodies
AU2006315580A1 (en) 2005-11-10 2007-05-24 Curagen Corporation Method of treating ovarian and renal cancer using antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen
WO2007062138A2 (en) 2005-11-23 2007-05-31 Applera Corporation Methods and compositions for treating diseases targeting human prominin-1(cd133)
DOP2006000277A (es) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
AR059900A1 (es) 2006-03-17 2008-05-07 Genentech Inc Anticuerpos anti-tat226 e inmunoconjugados

Also Published As

Publication number Publication date
EP1545613A2 (en) 2005-06-29
EP2357006A3 (en) 2011-10-19
US20080213289A1 (en) 2008-09-04
US20110064753A1 (en) 2011-03-17
WO2004010957B1 (en) 2004-08-19
EP2353611A2 (en) 2011-08-10
AU2003263964C1 (en) 2010-08-19
US20090324621A1 (en) 2009-12-31
CY2013004I1 (el) 2015-11-04
EP1545613A4 (en) 2008-10-15
HUS1300002I1 (hu) 2016-08-29
EP1545613B1 (en) 2011-07-20
WO2004010957A3 (en) 2004-06-10
EP2357006A2 (en) 2011-08-17
AU2010201459A1 (en) 2010-05-06
JP4741838B2 (ja) 2011-08-10
CA2494105A1 (en) 2004-02-05
EP1545613B9 (en) 2012-01-25
AU2003263964B2 (en) 2010-01-14
ES2369542T3 (es) 2011-12-01
ATE516818T1 (de) 2011-08-15
DK1545613T3 (da) 2011-11-14
US20100062008A1 (en) 2010-03-11
US20060074008A1 (en) 2006-04-06
WO2004010957A2 (en) 2004-02-05
US8906376B2 (en) 2014-12-09
FR12C0066I1 (enExample) 2012-12-14
EP2353611B1 (en) 2015-05-13
HK1157180A1 (en) 2012-06-29
SI2357006T1 (sl) 2016-01-29
US7659241B2 (en) 2010-02-09
SI1545613T1 (sl) 2011-11-30
PT2357006E (pt) 2016-01-22
CY2013004I2 (el) 2017-09-13
HUE027549T2 (hu) 2016-10-28
AU2010201459B2 (en) 2012-12-06
US7851437B2 (en) 2010-12-14
PT1545613E (pt) 2011-09-27
CA2802205C (en) 2016-01-19
JP2006500333A (ja) 2006-01-05
CA2494105C (en) 2013-04-02
AU2003263964A1 (en) 2004-02-16
ES2556641T3 (es) 2016-01-19
FR12C0066I2 (fr) 2013-08-16
ES2544527T3 (es) 2015-09-01
LU92133I2 (fr) 2013-03-18
CA2802205A1 (en) 2004-02-05
US7829531B2 (en) 2010-11-09
EP2353611A3 (en) 2011-10-19
EP2357006B1 (en) 2015-09-16
BE2012C047I2 (enExample) 2022-08-09
LU92133I9 (enExample) 2019-01-04
CY1111894T1 (el) 2015-11-04

Similar Documents

Publication Publication Date Title
DK2357006T3 (en) Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
JP4095444B2 (ja) ペンタペプチド化合物及びそれに関する使用
EP3273998B1 (en) Maytansinoid derivatives, conjugates thereof, and methods of use
US9463252B2 (en) Auristatin drug linker conjugates
DK2780039T3 (en) Cytotoxic peptides and antibody-drug conjugates thereof
CA3152316A1 (en) Camptothecin peptide conjugates
CN107213469A (zh) 能够与配体偶联的单甲基缬氨酸化合物
HK1157180B (en) Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
TW202412762A (zh) 奧瑞他汀衍生物及其結合物
HK1242628B (en) Maytansinoid derivatives, conjugates thereof, and methods of use
HK1242628A1 (en) Maytansinoid derivatives, conjugates thereof, and methods of use